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Summary and aim of the study 
 
Memory cells can persist for a whole lifetime. Consequently, these cells must possess 
characteristics which endows them with the capacity to survive in the absence of their 
cognate antigen, to self-renewal and to rapidly and efficiently respond upon 
secondary encounter of antigen. It has become increasingly clear that the memory 
pool can fulfil these diverse requirements because of its extreme heterogeneity which 
allows a division of labour among the different memory cell subsets. In my study I 
have investigated, together with my co-workers, the heterogeneity of the human 
CD4+T cell memory pool. These studies lead us to the identification of T cell 
memory subsets endowed with distinct immunological functions.  
On the basis of expression of the chemokine receptors CXCR5, CXCR3 and CCR4, 
we identified cells among the CD4+T central memory (TCM) pool, which represent 
unpolarized cells or precursors of TH1 or TH2 cells (pre-TH1, pre-TH2), respectively. 
We show that in homeostatic conditions CCR7+CXCR3+ and CCR7+CCR4+ cells 
are pre-committed to give rise to TH1 or TH2 effector cells, respectively, whereas they 
maintain a certain degree of flexibility of cytokine gene expression upon secondary 
encounter of antigen in the presence of polarizing cytokines. Importantly, these results 
could explain how the quality of primary T cell responses is maintained in the 
absence of antigen, therefore allowing a rapid and efficient secondary response upon 
antigenic re-encounter (manuscript 1). 
Furthermore, we investigated the signals that drive activated T cells to survive and 
generate long-lived memory T cells. We identified a subset of TCR-activated cells 
expressing CCR7 and the IL7R-α chain (CCR7+IL7Rhi cells), which possessed 
characteristics of memory cell precursors. However, we observed that CCR7+IL7Rhi 
cells were heterogeneous in their memory potential, depending on the signal strength 
they had received. In fact, CCR7+IL7Rhi cells generated at an intermediate strength of 
stimulation proliferated slowly with IL-7 and expanded efficiently upon secondary 
TCR stimulation, thus possessing characteristics of unpolarized TCM cells. In contrast, 
strongly stimulated CCR7+IL7Rhi cells expanded poorly upon TCR engagement but 
displayed a high proliferative rate with homeostatic cytokines. In the latter conditions 
they differentiated spontaneously to TH1 effector cells, a characteristic which is 
typical of circulating pre-TH1 cells. We conclude that the memory potential of CD4+T 
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memory cells is dictated by the strength of stimulation they receive, and is not 
necessarily predictable by phenotypic markers. Our results are consistent with the 
view that T-cell memory is generated at an intermediate range of signal strength, and 
they suggest that TCM and TEM subsets could be derived from CCR7+ precursors that 
received different amounts of stimulation (manuscript 2). 
Importantly, due to their antigen-experienced state, memory cells possess a lower 
threshold for proliferation compared to naïve cells and are thus more prone to 
autoreactivity. Autoreactivity may represent an important side effect of an anti-
microbial immune response and mechanisms have evolved that maintain self-
tolerance. In fact, in the peripheral blood of healthy individuals autoreactive T cells 
can be detected but are normally kept into check. We identified a subset of cells 
which seems to be involved in the maintenance of self-tolerance.  
In manuscript 3 we describe a population of antigen-experienced CD4+Foxp3- cells, 
distinct from natural Tregs, characterized by expression of the chemokine receptor 
CCR6. These cells secrete IL-10 in response to self-antigens and inhibit autoreactivity 
in an IL-10-dependent manner. Interestingly, we observed that in healthy donors, cells 
specific for MelanA, a self-antigen involved in the autoimmune disease vitiligo, are 
contained exclusively in the CCR6+ population, while in patients affected by vitiligo 
cells specific for MelanA can also be detected in the CCR6- population. Surprisingly, 
the CCR6+ population also contains cells that proliferate and produce IL-2 in 
response to recall antigens. We show that single CCR6+T cell clones can respond to 
self upon neutralization of IL-10, but proliferate vigorously and produce IL-2 in 
response to tetanus toxoid. These results suggest a context dependent function of 
these CCR6+T memory cells, in that they exhibit a Tr1-like suppressive capacity 
when exposed to self-antigens, thus limiting autoimmune reactions, while in the 
presence of their specific antigen they behave as normal memory cells. The 
mechanism we describe may represent a strategy evolved by the immune system 
which allows the utilization of slightly autoreactive T cells, thus broadening the TCR 
repertoire available for pathogen recognition, while lowering the risk of autoimmune 
reactions. 
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Riassunto e scopo del lavoro 
 
 
Le cellule della memoria possono persistere per tutta la vita. Pertanto queste cellule 
devono possedere caratteristiche che le rendano capaci di sopravvivere in assenza 
dell’antigene, di auto-rigenerarsi e di rispondere in modo rapido ed efficiente ad una 
successiva riesposizione all’antigene. Si e’ ora compreso che l’insieme delle cellule 
della memoria puo’ adempiere a compiti cosi svariati grazie all’estrema eterogeneita’ 
delle cellule che lo compongono, che permette una partizione dei compiti tra le 
diverse sottopopolazioni. In questo studio abbiamo analizzato l’eterogeneita’ delle 
cellule T CD4+ umane e abbiamo identificato sottopopolazioni che sembrano essere 
destinate a particolari funzioni nell’ambito del sistema immunitario. 
Abbiamo identificato diverse sottopopolazioni all’interno delle cellule T CD4+ 
“central memory” (TCM) sulla base dell’espressione di diversi recettori di chemokine. 
Abbiamo osservato che sottopopolazioni di TCM che esprimono CXCR5, CXCR3 e 
CCR4 rappresentano, rispettivamente, cellule non polarizzate o precursori di cellule 
TH1 (pre-TH1) o TH2 (pre-TH2). Qui mostriamo che in condizioni omeostatiche, 
cellule CCR7+ esprimenti CXCR3 e CCR4 sono pre-destinate a dare origine 
rispettivamente a cellule TH1 o TH2, mentre mantengono un certo grado di flessibilita’ 
in seguito ad un reincontro con l’antigene in presenza di citochine polarizzanti. La 
rilevanza di questo studio risiede nel fatto che potrebbe spiegare come viene 
mantenuta la qualita’ della risposta primaria in assenza dell’antigene, permettendo in 
questo modo alle cellule della memoria di generare risposte secondarie rapide ed 
efficienti (manoscritto 1). 
Abbiamo inoltre studiato i segnali che determinano se una cellula T attivata potra’ 
sopravvivere e generare una cellula della memoria. Abbiamo identificato una 
sottopopolazione di cellule, attivate tramite il TCR, che esprimono CCR7 e la catena 
α del recettore dell’IL-7 (cellule CCR7+IL7-Rhi) e che possiede caratteristiche di 
precursori di cellule della memoria. Inoltre abbiamo osservato che la sottopopolazione 
di cellule CCR7+IL7-Rhi e’ in realta’ composta da cellule eterogenee che, in base alla 
forza dello stimolo che hanno ricevuto, possiedono una diversa potenzialita’ a 
generare cellule della memoria. Infatti, cellule CCR7+IL7-Rhi che hanno ricevuto uno 
stimolo di forza intermedia, proliferano lentamente in presenza di IL-7 ma espandono 
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in maniera efficace in seguito a stimolazione antigenica, come osservato per cellule 
TCM non polarizzate. Diversamente, cellule CCR7+IL7-Rhi che hanno riceuvuto uno 
stimolo piu’ forte, proliferano poco in seguito ad una stimolazione antigenica ma si 
espandono rapidamente in presenza di citochine omeostatiche, differenziando 
spontaneamente in cellule TH1. Queste caratteristiche sono tipiche delle cellule pre-
TH1. Possiamo concludere che la capacita’ di generare memoria di cellule T CD4+ e’ 
determinata dalla forza del segnale con cui queste cellule vengono stimolate e non e’ 
necessariamente prevedibile sulla base di marcatori fenotipici (manoscritto 2). 
Le cellule della memoria, in quanto cellule che hanno precedentemente incontrato un 
antigene, possiedono una soglia di attivazione inferiore rispetto a cellule vergini o 
“naïve” e sono quindi maggiormente suscettibili a risposte autoimmunitarie. 
L’autoimmunita’ potrebbe costituire un importante e rischioso effetto collaterale di 
ogni riposta immunitaria anti-microbica e nel corso dell’evoluzione sono emersi 
diversi meccanismi atti a mantenere uno stato di non responsivita’ verso componenti 
autologhi (tolleranza verso il self). In effetti, nel sangue periferico di individui sani si 
possono riscontrare numerose cellule autoreattive che in condizioni normali vengono 
mantenute inattive. In questo studio abbiamo identificato una sottopopolazione di 
cellule della memoria che sembra essere implicata in questo processo di tolleranza 
verso il self. Qui descriviamo una popolazione di cellule CD4+Foxp3-, diverse dalle 
cellule Treg CD25+, caratterizzate dall’espressione del recettore delle chemokine 
CCR6. Queste cellule secernono la citochina IL-10 in seguito al riconoscimento di un 
auto-antigene ed inbiscono l’autoreattivita’ tramite un meccanismo dipendente 
dall’IL-10. Abbiamo osservato che in individui sani le cellule specifiche per MelanA, 
un autoantigene coinvolto nella malattia autoimmunitaria vitiligine, risiedono 
invariabilmente all’interno della sottopopolazione di cellule CCR6+. Diversamente, in 
pazienti affetti da vitiligine, le cellule specifiche per MelanA sono presenti anche 
nella sottopopolazione CCR6-.  
La popolazione CCR6+ e’ inoltre costituita da cellule specifiche per antigeni estranei, 
incontrati precedentemente nel corso di una risposta primaria, le quali proliferano e 
producono IL-2 ad una riesposizione all’antigene. Qui mostriamo che cloni CCR6+ 
possono rispondere sia ad un antigene autologo, in seguito alla neutralizzazione 
dell’IL-10, sia ad un antigene estraneo come il tetano. I risultati qui riportati 
suggeriscono che la funzione delle cellule CCR6+ sia legata al particolare contesto. 
Infatti queste cellule si comportano in modo simile a cellule “soppressorie” quando 
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riconoscono un auto-antigene e quindi impediscono una risposta autoimmunitaria. 
Invece in presenza dell’antigene per le quali sono specifiche, si comportano da 
normali cellule della memoria. Il meccanismo che descriviamo potrebbe rappresentare 
una strategia che il sistema immunitario mette in atto per poter utilizzare cellule che 
possiedono una bassa affinita’ per i componenti autologhi. Questo permetterebbe una 
maggiore disponibilita’ di repertorio per le risposte verso i patogeni ma al contempo 
limiterebbe la risposta verso componenti autologhi (manoscritto 3).  
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I. Introduction
1. Dendritic cells as bridges between innate and adaptive immunity
Healthy individuals protect themselves against microbes by means of many different
mechanisms. These include physical barriers, phagocytic cells and eosinophils in the
blood and tissues, natural killer (NK) cells, and various blood-borne molecules, all of
which participate in defending individuals from a potentially hostile environment. All
of these defense mechanisms are present prior to exposure to infectious microbes or
other foreign macromolecules, they are not enhanced by such exposures, and do not
discriminate among most foreign substances. These are the components of the natural
or innate immunity1, 2. Differently, there are other defense mechanisms that are
induced or stimulated by exposure to foreign substances. These mechanisms are
extremely specific for distinct macromolecules, and increase in magnitude and
defensive capabilities with each successive exposure to a particular macromolecule.
They constitute the acquired or adaptive immunity, as they occur during the lifetime
of an individual as an adaptation to infection with a pathogen. Foreign substances that
induce specific immunity are called antigens. Adaptive immunity is a sophisticated
antigen-specific defense system which is present only at higher levels of evolution
and consists of T and B lymphocytes and their secreted products, such as antibodies.
The particular feature of adaptive immune responses to “remember” the first
encounter with a pathogen, is at the basis of the so-called “immunological memory”,
and leads to an enhanced and more efficient response following reinfection with the
same pathogen. The study of the complex mechanisms driving T and B lymphocyte
memory generation is instrumental for the design of optimal vaccines which have
already protected humans from many life-threatening diseases.
Dendritic cells (DCs) were first described more than thirty years ago and have been
shown to be the only cell type which can initiate a primary immune response3, 4. On
one hand they possess the capacity to recognize pathogens, and on the other hand they
are able to activate cells of the adaptive component of the immune system, thus
constituting an important bridge between innate and adaptive immunity. DCs express
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a broad repertoire of Toll-like receptors (TLRs), which are innate receptors that
recognize distinct microbial products and trigger dendritic cell maturation and
cytokine production5. After challenge with microbial or inflammatory stimuli,
immature DCs undergo a complex process of maturation, resulting in their migration
from tissues to secondary lymphoid organs and up-regulation of major
histocompatibility complex (MHC) and co-stimulatory molecules, that are essential
for the activation of cells of the adaptive immune system, such as T lymphocytes6, 7.
Two subsets of DCs can be identified in human peripheral blood8. The first is
represented by myeloid DC (mDC) which express CD1c, mature in response to a
variety of stimuli, but produce IL-12 primarily in response to LPS or CD40L
stimulation. The second subset is represented by plasmacytoid DC (pDC), which
produce very high levels of IFN-α upon exposure to viruses. Furthermore, peripheral
blood monocytes are considered as precursors of DCs9. Monocytes can be
differentiated in vitro upon exposure to granulocyte/macrophage colony stimulating
factor (GM-CFSF) and interleukin-4 (IL-4) to cells with characteristics similar to
those of mDCs5. However, the situation in vivo appears to be more complex as recent
work suggested that mDCs can derive from lymphoid or myeloid progenitors10.
2. T cell maturation and induction of central tolerance
T lymphocte precursors arise in the bone marrow and subsequently migrate to the
thymus where they undergo maturation. In the thymus, T cells learn to discriminate
between self and non-self, in that on one side they are able to recognize foreign
antigens in association to self-MHC molecules, but on the other side they will not
attack self-components. This process is termed “central tolerance” and involves a
phase of positive selection of T cells, which are selected for the ability to recognize
through their T cell receptor (TCR), self-MHC/peptide complexes presented by
thymic epithelial cells. Failure of such recognition within a certain window of
affinity/avidity is interpreted as reflecting a useless specificity, i.e. lack of self-MHC
restriction, and results in death by neglect of the respective T cell. T cells also
undergo a phase of negative selection, where those cells that recognize peptide-MHC
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complexes with too high affinity are deleted by apoptosis11. As a result, the mature T
cells which exit the thymus are self MHC-restricted and self-tolerant.
Recent data have pointed out an important role for thymic medullary promiscuous
gene expression in the process of negative selection. In fact surprisingly, RNA
transcripts encoding proteins previously considered to be synthesized only in
particular peripheral tissues were detected in the thymus, in particular in medullary
thymic epithelial cells (mTECS)12. Several mouse models have revealed a direct link
between ectopic synthesis of a designated protein in mTECs and the absence of
peripheral lymphocyte reactivity to that protein. Many of the ectopically expressed
antigens, (insulin, thyroglobulin, myelin basic protein, and retinal S-antigen) are
associated with organ-specific autoimmune diseases (type 1 diabetes, thyroglobulin,
multiple sclerosis and uveitis, respectively). Interestingly, there are some very
suggestive correlations between antigen expression levels in the thymus and disease
susceptibility in humans and rodents. An important clue towards understanding the
regulation of this ectopic expression has been the finding that a protein with the
features of a transcription factor, termed AIRE (autoimmune regulator), controls the
expression of numerous genes in murine mTECs, with a predilection for tissue-
restricted antigens. This important finding was further documented in humans with
the observation that patients affected by the multiorgan autoimmune endocrine
disease APECED (autoimmune polyendocrinopathy-candidiasis-ectodermal
dystrophy) presented mutations in the AIRE gene13. Two groups generated the AIRE-
deficient mouse which presented a phenotype that was very similar to that of patients
affected by APECED. AIRE deficient mice were characterized by a broad
autoreactivity directed towards specific structures in many organs and analyses of
these organs revealed lymphocytic infiltrates and presence of autoantibodies14, 15.
3. T cell activation
Conventional T cells bear a T cell receptor composed of an α and β glycoprotein
chain (TCR-αβ) and recognize antigen in association with MHC molecules displayed
on the surface of APCs. Furthermore, a minor subset of T cells exists which possess a
TCR composed of a γ and a δ chain (TCR-γδ). These cells are particularly abundant in
the gut. Mature TCR-αβ  T cells can be subdivided into functionally distinct
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populations expressing the membrane proteins CD4 or CD8. CD4+T cells are
generally considered as “helper” T cells (TH) and CD8+T cells as “cytotoxic” T cells
(CTL), although additional features have now been identified for these populations.
When mature, antigen unexperienced, “naïve” T cells leave the thymus they
continuously recirculate from the blood to secondary lymphoid organs and, within the
T cell areas of these organs, they encounter DCs carrying antigen taken up locally or
in peripheral tissues. The outcome of naïve T cell antigenic stimulation can lead to
divergent responses that range from deletion of antigen-specific lymphocytes and
tolerance to the generation of a large number of effector cells, followed by
establishment of immunological memory.
The generation of such different T cell fates is dependent upon the strength of
stimulation the T cell receives through its TCR interacting with peptide-MHC
displayed on the surface of antigen-presenting cells (APCs), and the overall cytokine
environment. The strength of T cell stimulation in turn is determined by different
factors which all contribute and partially compensate each other: the concentration of
and affinity for the antigen, which determines the rate of TCR triggering16-18, the
presence or absence of co-stimulation, which regulates the extent of signal
amplification19-21, and the duration of the interactions between T cells and DCs, which
determines the duration of the signaling process22, 23. Thus, T cells accumulate signals
and gradually acquire “fitness”- defined as resistance to cell death and responsiveness
to homeostatic cytokines- as a function of signal strength. These signals drive T cell
differentition by converging in a coordinated fashion in the regulation of
transcriptional programmes that control the cell cycle, responses to cytokines,
migratory capacity, effector function and susceptibility to activation-induced cell
death (AICD). Consequently, the different T cell fates can be explained by a
differential activation of some transcriptional programmes at a low strength of
stimulation, whereas others require a higher strength of stimulation, as well as
additional signals delivered by cytokines. This concept was proposed in the
“progressive differentiation model”, which was also used to explain the generation of
different memory subsets, and will be discussed further on.
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4. Generation of T cell memory
In the course of a primary response three stages can be identified. The first stage, the
“expansion” phase, is initiated in the lymphoid tissue where naïve T cells encounter
their specific antigen presented by DCs, they clonally expand and differentiate into
effector cells. Through the combined ability of CD4+T and CD8+T effector cells to
secrete inflammatory cytokines and kill infected cells, a typical acute viral infection in
mice can be cleared within days. Over the weeks that follow pathogen clearance, the
majority (90%) of effector cells die, and this stage is often referred to as “contraction”
period. The surviving T cells enter the third stage, the “memory” phase, in which the
number of memory T cells stabilizes and can be maintained for a whole lifetime in the
absence of antigen. Compared to naïve T cells, memory cells show more rapid and
enhanced responses to antigenic stimulation, thus conferring better protection against
secondary infections by the same pathogen.
Maintenance of memory T cells is achieved through a continuous and slow turnover of
cells dependent upon the homeostatic cytokines IL-7 and IL-15, which belong to the
common cytokine receptor γ-chain family (γc or CD132 cytokines) 24, 25. In particular, it
was shown that IL-15 is important for maintaining CD8+ memory T cell numbers in
vivo, while IL-7 seems to have a major role in the survival of naïve and memory
CD4+T cells26. It was shown recently that IL-7-R-derived signals play a non-redundant
role for the generation of memory T cells in the mouse. Thus in the absence of IL-7 no
memory T cells develop27-29. Furthermore, CD8+ T memory cell precursors can be
identified by IL7-Rα chain expression early at the peak of the proliferative response30.
These memory cell precursors showed enhanced survival, homeostatic proliferation and
recall responses upon antigenic restimulation both in vivo and in vitro.
5. Heterogeneity of human memory T cells
5.1 CD4+T cells: TH1-TH2 versus Tr1
Naive CD4+ T helper (TH) cells can undergo extremely different fates depending on
the context in which they encounter their specific antigen. They can polarize towards
T helper 1 (TH1) or TH2 cells which produce different sets of cytokines and mediate
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protection from intracellular or extracellular pathogens respectively, or may be
involved in B cell help31, 32. TH1 cells are characterized by secretion of interferon-γ
(IFN-γ)) and induction of cell-mediated responses against intracellular pathogens,
including bacteria, parasites, yeast and viruses. TH2 cells produce IL-4, IL-5, IL-10
and IL-13 and mediate protection against extracellular parasites and helminthes.
As well as their protective roles in host defense, both subsets of TH cells have been
implicated in pathological responses. TH1 cells are involved in autoimmunity
33, and
TH2 cells have been implicated in the pathogenesis of asthma and allergy
34-36. The
balance between TH1 and TH2 cells is therefore critical in determining whether
specific immunity against invading pathogens is successful and in avoiding
pathological manifestations. TH1 and TH2 cells cross-regulate each other’s function
and development, in that IFN-γ produced by TH1 cells inhibits the development of
TH2 cells, whereas production of IL-4 and IL-10 by TH2 cells inhibits TH1
development and activation.
It is widely accepted that the cytokines IL-12 and IL-4 are the key determinants in
promoting TH1 or TH2 cells, respectively. Exposure of cells during TCR engagement
to IL-12 or IL-4 leads to activation of specific transcription factors which are
important in specifying the TH1/ TH2 phenotype, at least in part through regulation of
chromatin structure and accessibility of cytokine genes. IL-12 and IL-4 act through
signal transducer and activator of transcription (STAT4) or STAT6, respectively,
which induce distinct signaling pathways. TH1 cells express the transcription factor T-
bet which induces remodeling of the endogenous ifn−γ locus and expression of the IL-
12 receptor β2 subunit (IL-12Rβ2), thus increasing release of IFN-γ and response to
IL-12. TH2 cells express the transcription factor GATA-3 which plays an important
role in inducing expression of TH2 type cytokines
37.
TH2 cells and TH2 derived cytokines, in particular IL-10, have been shown to play a
“regulatory” role in the process of cell tolerance through their capacity to inhibit
immune responses. But now it is clear that specialized populations of regulatory T
cells exist and can result from the stimulation of naïve CD4+ T cells in sub-optimal
conditions. These cells have been named T regulatory 1 cells (Tr1) and will be
discussed further on.
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5.2 Migratory capacity reflecting effector function
Accumulating evidence indicates that during the T cell differentiation process,
effector function and migratory capacity are coordinately regulated and as T cells
polarize and acquire the capacity to produce a given cytokine they also acquire new
migratory properties. The intimate connection between migratory capacity and
function of a given T cell assures that the right cell will be at the right place at a given
moment. The regulation of leukocyte migration is a complex process involving the
sequential participation of adhesion molecules, such as selectins and integrins38, as
well as chemokines and chemokine receptors39. The combined action of adhesion
molecules and chemokines is thought to provide an address code for leukocyte
migration to different sites40. It is thus not surprising that TH1 and TH2 cells
preferentially express different sets of chemokine receptors which guide them to sites
where their function is needed.
Chemokines interact with G protein-coupled receptors possessing a seven
transmembrane domain on their target cells, and receptor expression is a crucial
determinant of the spectrum of action of chemokines41. Chemokines can be divided
into different families (CC, CXC, CX3C and C) according to the presence and the
relative position of the NH2-terminal cystein residues. Alternatively, they can be
classified as homeostatic (constitutive) or inflammatory (inducible) according to their
function. Homeostatic chemokines are expressed constitutively and appear to be
responsible for trafficking of lymphocytes under conditions of homeostasis. In
contrast, inflammatory chemokines are specifically up-regulated at sites of
inflammation and are thought to play a role in the recruitment of lymphocytes to
peripheral tissues in response to immunological challenge.
TH1 cells preferentially express the chemokine receptors CCR5, CXCR3 and CCR1.
In rheumatoid arthritis and multiple sclerosis, thought to be TH1-associated diseases,
virtually all T cells in the lesions express CCR5 and CXCR3, although usually only 5-
15% of peripheral blood T cells have this phenotype. CCR1 and CCR5 are also
expressed on monocytes and macrophages, and this explains their co-localization with
TH1 cells. TH2 cells express CCR3 which is also expressed by eosinophils and
basophils, and the shared expression may allow these cells to co-localize at sites of
production of eotaxin, the ligand of CCR3. Besides CCR3, TH2 cells also express
CCR4, a receptor for TARC and MDC, important for DC-T interaction and also
12
expressed by basophils, CCR8, the receptor for I-309, and CrTh2, the ligand for
prostaglandin D2. Of notice, some chemokine receptors are only preferentially
expressed by TH1 or TH2 cells but may also be produced at lower levels by the
opposite subset 42, 43.
5.3 T cell homing to skin versus gut and role of CCR6
The vast majority of antigens contact the body either at mucosal surfaces, in particular
the intestine, or at the level of the skin. Increasing evidence shows that the
microenvironment of these barriers has an influence on the immune response that
develops locally. The gut mucosal environment is rich in the immunosuppressive
cytokines IL-10 and TGF-β, which are believed to play a role in maintaining a state of
unresponsiveness of lymphocytes to innocuous antigens deriving from food and
commensal bacteria44. Interestingly, it was shown that DCs from Peyer’s patches
produce high levels of IL-10 and constitutively express TGF-β mRNA, thus
polarizing the immune response in an anti-inflammatory direction45.
It has been proposed that during T cell priming, tissue-derived APCs within cutaneous
versus intestinal secondary lymphoid organs imprint the corresponding tissue-specific
homing phenotype to the T cell, such that the primed T cells have a predisposition to
home back to the skin or gut, respectively46, 47. Chemokine receptors expressed in
combination with adhesion molecules were shown to allow tissue-specific homing of
a particular T cell subset. Thus, the simultaneous expression of the cutaneous
lymphocyte-associated antigen (CLA), binding to E-selectin, and CCR4 identifies
skin-homing T cells48. Conversely, expression of the integrin α4β7 (binding to
mucosal adressin cell-adhesion molecule-1, MADCAM-1) and CCR9 (binding to
CCL25) is characteristic of gut-homing T cells49. Not only do the skin-homing and
gut-homing populations of cells expressing these markers home preferentially to these
tissues, but also immunity to cutaneous and intestinal antigens, respectively, resides
within them50. The integrin αEβ7, which binds to E-cadherin, was initially described
as a marker for T cells residing in the gut, but data from αE deficient mice suggested
an additional role of this molecule in the control of cutaneous inflammation51, 52.
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Another chemokine-receptor pair, CCR6 and its ligand CCL20/MIP-
3α/LARC/Exodus, seems to be involved in controlling migration to mucosal surfaces,
in particular the gut, and to the skin53. CCR6 is expressed on B cells, memory T cells,
including skin-homing CLA+ and mucosa-homing α4β7+ cells, and immature DCs,
including immature Langerhans cells. Immature DCs were proposed to have a central
role in inducing peripheral tolerance54. Importantly, in humans, expression of CCR6
was also detected on a subset of suppressive DCs that over-express the enzyme
indoleamine 2,3-dioxygenase (IDO)55. It was reported that a “chemokine receptor
switch” characterized by loss of CCR6 and gain of CCR7 expression occurs as DCs
transition from immature cells, preferentially localized at epithelial sites to mature
antigen-loaded cells, that home to T cell areas of draining lymphnodes56.
CCL20 is thought to act both as an homeostatic and inflammatory chemokine, and it
is expressed constitutively in several lymphoid and non lymphoid tissues (mainly
tissues such as the skin and gut), although its expression is up-regulated with
inflammation. Furthermore, human β-defensins, which are anti-microbial peptides
released by epithelial cells at mucosal surfaces or in the skin following a pro-
inflammatory stimuli, have been reported as non-chemokine ligands for CCR653.
Two research groups independently generated the CCR6 knock-out mouse and
reported similar findings57, 58. These mice were characterized by the absence of
subsets of DCs expressing CD11c and CD11b from the sub-epithelial dome of
Peyer’s patches and a 2-fold increase in the number of total lymphocytes and T cells
within the mucosa. A closer analysis showed that this modest increase in total
lymphocytes was due to much larger relative increases in several subpopulations of
lymphocytes. The majority of the increased T cells were TCR-αβ T cells, while there
was little or no increase in TCR-γδ T cells. Activated CD69+T cells, CD4+T and
CD4+CD8+T were largely increased in the intestinal mucosa, but this was not
accompanied by an increase in other sites. Furthermore, in T cell priming experiments
CCR6 deficient mice presented altered T cell responses which varied considerably
according to the experimental model of inflammation used55,57,58. In fact, in 2,4-
dinitrofluorobenzene (DNFB)-induced contact hypersensitivity studies these mice
presented a more severe and more persistent inflammation than wild-type animals.
The authors suggest a possible defect in the CD4+T cells responsible for down-
regulating the DNFB-induced inflammation. In contrast, in a delayed-type
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hypersensitivity model CCR6 defective mice developed no inflammatory response,
which the authors suggest is due to an altered effector CD4+T cell response. These
results seem to indicate that CCR6 identifies CD4+T cells possessing different
functions, such that lack of these cells can impair either effector or “regulatory” T cell
functions58.
Several reports also suggest a role for CCR6/CCL20 in autoimmune diseases
including psoriasis, inflammatory bowel disease and rheumatoid arthritis18, 59-63.
Indeed, CCL20 was expressed at higher levels in the synovial fluid of patients
affected with rheumatoid arthritis, and both CCR6 and CCL20 were up-regulated
within psoriatic lesions.
5.4 Central memory and effector memory T cells
A futher heterogeneity of memory T cells has been recently proposed. Two subsets of
CD4+ and CD8+ memory T cells have been identified in both humans and mice,
based on functional and homing properties64, 65.
Human memory T cells were defined according to expression of the lymph node
homing receptors CCR7 and CD62L, which are characteristic of naïve T cells and are
required for cell extravasation through high endothelial venules (HEV) and migration
to T cell areas of secondary lymphoid organs (Figure 1)66, 67. T central memory cells
(TCM) constitutively express CCR7 and CD62L and produce mainly IL-2 following
TCR triggering, thus they lack immediate effector function but proliferate and
become effector cells upon secondary stimulation. Conversely, T effector memory
cells (TEM) have lost the constitutive expression of CCR7, are heterogeneous for
CD62L expression and express receptors involved in homing to inflamed tissues.
Following TCR triggering, TEM cells rapidly produce effector cytokines IFN-γ, IL-4
and IL-5, and CD8+ TEM cells also release large amounts of perforin. Thus in humans,
the TEM pool contains bona fide TH1, TH2 and CTL.
The existence of two subsets of memory cells with distinct functions and migratory
potential suggests a subdivision of tasks among memory cells. On one hand, TEM cells
represent a readily available pool of antigen-primed cells which can enter peripheral
tissues due to expression of tissue-homing receptors and can give immediate
protection. On the other hand, TCM cells represent a “stem cell like” pool of antigen-
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primed cells, which travel to secondary lympoid organs due to expression of CCR7
and, upon a secondary challenge, can rapidly and efficiently generate a new wave of
effector cells. In fact, data obtained in vitro with CD4+ human memory T cells show
that TCM cells expanded with homeostatic cytokines lose CCR7 expression and aquire
CCR5 as well as the capacity to produce high levels of IFN-γ and IL-4, comparable to
those produced by effector cells. Thus TCM cells differentiate efficiently and generate
cells with the characteristics of TEM in an antigen-independent fashion. The behaviour
of TCM cells is different from naïve T cells which, expanded in the same condition,
retain lymph node homing phenotype (CD45RA+CCR7+) and undergo only very
limited differentiation68. Similarly, cytokine-stimulated CD8+ TCM cells differentiate
and generate various types of effector cells expressing CCR7, perforin and CD45RA
in different combinations. Single cell cloning of CD8+ TCM cells with homeostatic
cytokines revealed that this population is heterogenous in that TCM cells are
programmed to generate different types of effector cells under homeostatic
conditions69.
The presence of memory cells with different migratory capacity and effector function
was also documented in mice. Two populations of memory CD4+ T cells survive for
months after immunization of antigen in adiuvant: a population of cells producing IL-
2 was found primarly in the lymph nodes, while another larger population producing
IFN-γ was found in non lymphoid tissues 70. Similarly, two populations of antigen-
specific memory CD8+ T cells are detected following bacterial or viral infection64.
Whereas CD8+ memory T cells isolated from non lymphoid tissues exhibit lytic
activity directly ex vivo, their splenic counterparts do not. These results allowed to
extend the TEM/ TCM paradigm to the mouse system.
Since the first description of TCM and TEM it soon became evident that these two broad
subsets of memory cells are heterogeneous in expression of chemokine receptors,
adhesion and costimulatory molecules.
5.4.1 Heterogeneity of TCM and TEM cells
Primed and unprimed T cells can be distinguished on the basis of expression of the
different isoforms of the leukocyte common antigen (CD45), a transmembrane
tyrosinase phosphatase important for antigen receptor signal transduction71. Naïve T
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cells express the isoform CD45RA which is progressively downregulated following
TCR triggering and is accompanied by an increase in CD45R0 expression72. Human
memory T cells are mostly CD45RO+CD45RA-, except for a small subset of
CD8+CCR7- cells (CD8+TEMRA) which re-express CD45RA and are believed to
represent the most differentiated type of memory cell. Human CD8+TEMRA, specific
for lytic but not latent Epstein-Barr virus antigens, have been detected after the acute
phase of viral infection but were absent in persistent HIV infection. In vitro data
suggests that CD45RA re-expression on antigen-experienced CD8+ T cells is
inhibited by antigen and promoted by homeostatic cytokines, consistent with the
selective and late appearance of TEMRA cells in viral infections
69. More recently, a
similar subset of cells was also described in the human CD4+ T cell compartment
(CD4+ TEMRA) 
73, 74. Human TCM and TEM can be subdivided into functional subsets on
the basis of expression of the chemokine receptors described for TH1 and TH2 cells,
and of other markers (Figure 1)75.
A proportion of circulating TCM express CXCR5, a chemokine receptor also expressed
by B cells and whose ligand CXCL13 is expressed in B cell follicles. CXCR5+T cells
are unpolarized and upon TCR triggering secrete mainly IL-2 and some IL-10, and
were suggested to be involved in delivering help to B cells. Cells with this phenotype
have also been identified in tonsils and were named follicular B helper T cells (TFH)
due to their capacity to potently induce antibody production during coculture with B
cells. However, subsequent work demonstrated that the B cell helper activity was
restricted to only a small subset of tonsillar CXCR5+ CD57+ cells76-78.
Chemokine receptors are expressed in combination with adhesion molecules,
allowing tissue-specific homing of a particular T cell subset. For example as
explained previously, the simultaneous expression of CLA and CCR4 identifies skin-
homing T cells48, whereas the expression of α4β7 and CCR9 is characteristic of gut-
homing T cells49. Some skin and gut-homing T cells express CCR7, suggesting that
they may be able to home to lymphoid as well as non-lymphoid tissues79.
It should be noted that some of the described markers are rapidly and transiently
modulated upon cell activation, thus the phenotypic characterization of TCM and TEM
applies only to resting cells, i.e. those that are not engaged in an antigen-driven
response.
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Figure 1. Phenotypic heterogeneity of human memory T cells (adapted from Sallusto et al. Annu. Rev.
Immunol. 2004, 22:745-63).
6. Lineage relationship of memory T cell subsets
The lineage of memory T cells remains only partially understood and it is still
controversial whether memory cells are direct descendents of effector cells or whether
they arise independently from a separate lineage.
According to the “progressive differentiation model”, proposed by Lanzavecchia-
Sallusto & co-workers, signal strength plays a major role in the differentiation of
effector and memory cells, with the generation of memory cells occurring over a
precise range of strength of stimulation (Figure 2a)38. Stimulatory conditions which are
below or above this productive range lead to cells which either die by neglect or are
deleted by activation induced cell death, respectively. Within the productive range it is
possible to generate cells which belong to a variety of differentiation stages ranging
from effectors to cells that have been arrested at intermediate levels of differentiation,
and possess distinct homing capacities. The latter cells represent precursors of TCM cells
and are maintained throughout the whole lifetime. Thus, within the same immune
response T cells can receive different levels of signal strength either because the
number and duration of T-APC interactions are stochastic events80, or because T cells
may be recruited at different times. In fact, at early stages of the immune response,
there will be large numbers of mature DC carrying high doses of antigen and secreting
large amounts of polarizing cytokines, while at later time points the stimulatory
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conditions may change substantially with arrival of fewer DC, which carry low
amounts of antigen and have exhausted their cytokine-producing capacity81. According
to this model, precursors of TEM would be preferentially generated early on, whereas
precursors of TCM would be preferentially generated at late stages of the immune
response. The model proposed above is consistent with the observation that memory
precursors are not present at the peak of the immune response but progressively appear
during the contraction phase coincident with global changes in transcriptional
profiling82. As mentioned previously, data obtained in vitro with human memory T
cells indicate that TCM can generate TEM upon cytokine or antigen stimulation, whereas
TEM could either further differentiate (for instance acquire additional cytokine
producing capacity) or retain the original imprinted phenotype68, 83. In contrast with
these observations, TCR repertoire analyses of human CD8+ TCM and TEM cells
revealed that the two populations have a stable repertoire over a long period of time,
but share few common clonotypes84. The largely distinct repertoires between CD8+
TCM and TEM cells seem to suggest that TEM cells may not have derived from TCM cells,
but that the two populations are distinct and are generated independently. Alternatively,
the precursors of TEM cells within the TCM pool may have disappeared, do not re-
circulate in blood, or have reached an undetectable frequency85. Further studies will be
required to distinguish between these possibilities. Recently, it was shown for human
CD4+T memory cells that TEM have a much more rapid in vivo turnover compared to
TCM, indicating that TEM represent a short-lived cell population that requires continuous
replenishment86. This is compatible with a model in which long-lived TCM cells
continuously replenish the pool of TEM cells, but could also suggest that the two
populations are maintained as separate pools with distinct turnover rates.
Another model proposed by Ahmed and co-workers and called the “linear
differentiation” model, was based on data obtained with CD8+T memory cells in the
mouse system (Figure 2b). This model states that memory cells are direct descendents
of effector cells, thus memory does not develop until antigen is cleared or greatly
decreased in concentration, and the precursors of memory cells are true effector cells.
According to this model, TEM cells are only a transitory population representing an
“intermediate” cell type in the effector to memory transition, and in the absence of
antigen they convert directly into TCM, which are the true memory cells, and only then
gain the ability to undergo efficient homeostatic turnover. Indeed, it was shown that
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Figure 2. Models of memory T cell generation.
(2a)  Model 1: Progressive differentiation model for T cell differentation and memory T cell
generation. The duration and intensity of antigenic stimulation is indicated by the length and thickness of
solid arrows. Antigen-independent events leading to T cell proliferation and differentation are indicated
by the dotted lines. AICD, activation induced cell death (adapted from Sallusto et al. Ann.Rev.Immunol.
2004, 22:745-63) (2b) Model 2: Linear progressive differentiation model of memory CD8 T cell
precursors during the contraction phase following antigen clearance. Memory T cells generate
directly from effector cells during the expansion phase and gradually acquire memory cell properties
(adapted from Kaech et al. Cell 2002, 111: 837-851).
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cells with TEM characteristics (cytotoxicity and low expression of CD62L) when
adoptively transferred into naïve recipients, were able to “revert” to TCM
87. As
mentioned previously, further studies from the same group showed that at the peak of
the CD8 response there is a small fraction of effector cells (typically CD62L negative)
with high expression of CD127, the IL7R-α chain, which possess characteristics of
memory cell precursors30. Adoptive transfer in naïve recipients of IL-7Rhi and IL-7Rlo
effector cells showed that IL-7Rhi cells preferentially gave rise to memory cells that
could persist and confer protective immunity. Other groups described CD8+T cell
expression of the IL7R-α chain as an early marker of memory T cells in vivo88, 89. In
particular they showed that IL7R expression combined with that of CD62L, could
distinguish between functionally distinct memory T cell subsets. These cells possessed
the characteristics of previously described central memory T cells (IL7Rhi CD62Lhi)
and effector memory T cells (IL7Rhi CD62Llo).
7. Mechanisms of peripheral tolerance
T cell tolerance is established early during T cell development in the thymus by
deletion of autoreactive T cells (central tolerance). However, this deletion is not
complete as there is evidence that potentially dangerous self-reactive T cells are
present in the periphery of healthy individuals90. These T cells are kept in check by
additional mechanisms which go under the name of “peripheral tolerance” and act on
mature T lymphocytes that have left the thymus. Peripheral tolerance is achieved by
mechanisms which include functional inactivation, physical deletion of autoreactive T
cells, ignorance and suppression by specialized T cell populations91.
7.1 Functional inactivation
At least two signals are required for optimal T cell activation. The first signal, which
ensures specificity of the response, is delivered by TCR interaction with MHC and
peptide, while the second signal involves ligation of co-stimulatory molecules and is
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needed for enhancing cytokine production, augmenting cell proliferation and cell
survival. Antigen recognition in the absence of co-stimulation may lead to a state of
functional unresponsiveness, also called anergy. This state was first demonstrated in
CD4+T cell clones in which antigen receptors were engaged without co-stimulation.
In the absence of co-stimulation T cells were unable to proliferate, unable to produce
IL-2 but were not deleted92, 93. This situation could resemble the in vivo presentation
of self-antigens in peripheral tissues, which are normally presented to the T cells in
the absence of inflammation. Furthermore, it seems that anergy can also be induced
by foreign antigens administered without adiuvant.
There is evidence that in vivo T cell anergy may be induced not only because of a
lack of co-stimulation, but as a result of specific recognition of B7 molecules by
CTLA-4. These evidences pointed out an important role for interaction of either
CD28-B7 or CTLA-4-B7 on the outcome of antigen recognition by T cells94.
7.2 Physical deletion
Autoreactive T cells can be physically deleted by apoptosis,  which can be induced by
opposing signals such as repeated antigenic stimulation, “activation induced cell
death” (AICD), or inadequate survival stimuli, “death by neglect”.  Although both
pathways of apoptosis share the same terminal effector phase and show the same
morphological and biochemical manifestations, their induction, molecular controls
and physiological functions are largely distinct. AICD is induced by repeated
stimulation, with high levels of IL-2 production and is not prevented by the anti-
apoptotic molecules Bcl-2 or Bcl-XL. Under these conditions, T cells co-express death
cytokines such as FasL and TNF-α which interact with their respective receptors and
recruit and activate caspases leading to apoptotic death of the T cell. In fact,
autoreactive T cells in the periphery repeatedly encounter persistent self-antigen
leading to co-expression of death cytokine-receptor pairs and apoptotic death of the T
cell. Mice with defects in Fas, FasL, IL-2R-α or β chain exhibit defects in AICD and
develop a lupus-like autoimmune disease, which is due to abnormally prolonged
survival of autoreactive helper T cells and an inability to eliminate self-reactive B
lymphocytes by apoptosis95. Furthermore in humans, mutations in the fas gene are
associated with a lymphoproliferative autoimmune syndrome96.
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At the other extreme, both naïve or activated T cells can die “by neglect” because of
lack of survival stimuli, such as co-stimulators and cytokines. This form of apoptosis
is distinct from that of AICD since it does not involve death cytokines and death
receptors97. Following growth factor withdrawal in fact, cells experience a metabolic
arrest causing mitochondrial damage and release of cytochrome c into the cytoplasm,
with consequent activation of caspases and death by apoptosis. Differently from
AICD, over-expression of anti-apoptotic molecules Bcl-2 or Bcl-xL in lymphocytes
prevents death by neglect98, 99.
7.3 Ignorance
Some self-antigens fail to induce an immune response simply because they are
ignored by the immune system. This occurs when antigens are expressed in immuno-
priviledged sites, where they are anatomically sequestered in a tissue and do not reach
organized lymphatic tissues in sufficient amounts. Alternatively antigens could lack
an appropriate presentation to lymphocytes in an inflammatory context by mature
APCs. Potentially, these self-antigens could induce autoimmune pathology if an
unrelated infection would cause their release and presentation in an immunogenic
inflammatory context100.
7.4 Suppression
There is now convincing evidence that, in addition to the mechanisms of self-
tolerance described above, a specialized population of CD4+ T cells, called regulatory
T cells (Tregs) exists. Tregs are involved in the maintenance of peripheral self-
tolerance by actively suppressing the activation and expansion of self-reactive T cells.
Two major populations of Tregs have been described so far, naturally occurring and
adaptive or IL-10-secreting Tregs (Table 1).
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8. Regulatory T cells
8.1. Naturally occurring T regulatory cells
Different findings, the first of which were made thirty years ago, suggested the
existence within the CD4+T cell population, of a subset of CD4+T cells endowed
with an autoimmune-inhibitory activity101. Furthermore, it was shown that in mice a
population of cells contained within CD4+CD45Rblow cells (which constitute the
compartment of activated CD4+T cells found in normal mice) was able to control
colitis induced by the transfer of CD4+CD45Rbhigh (naïve) cells102, 103. Finally,
Sakaguchi and co-workers proposed CD25, the α-chain of the IL-2 receptor, as a cell
surface marker which could identify this suppressor population104. CD4+CD25+T
cells also called “naturally occurring” Tregs, were initially described in mice as
naturally anergic and suppressive cells, produced by the thymus as a functionally
distinct subpopulation of T cells and involved in maintaining self-tolerance. Evidence
is now accumulating that Tregs are also involved in controlling immune reactivity
towards foreign antigens105. Removal of CD25+ Tregs leads to a spontaneous
development of various autoimmune diseases in otherwise normal mice. Furthermore,
the removal of these cells also triggers excessive or misdirected immune responses to
microbial antigens, causing immunopathologies such as inflammatory bowel disease
(IBD) which is due to hyper-activation of the remaining T cells to commensal bacteria
in the intestine103.
At first, these cells where thought to be produced exclusively in the thymus but more
recent data also suggested that, in vivo, they could be derived de novo from naïve T
cells in the periphery after a prolonged exposure to low doses of antigen106. These
cells were phenotypically and functionally indistinguishable from intra-thymically
derived Tregs. There is also evidence that mouse CD25+Tregs can be generated in
vitro from peripheral CD25-CD4+T cells stimulated through their TCR in the
presence of TGF-β. These “converted” Tregs inhibited CD4+T cell proliferation when
transferred in vivo107.
CD4+CD25+Tregs have also been identified in human peripheral blood and when
assayed in vitro showed similar characteristics to mouse Tregs108. In both rodents and
humans, CD4+CD25+T cells represent 5-10% of the CD4+T lymphocytes.
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Although CD25, the IL-2Rα chain, was widely used as a marker for identifying Tregs
in both humans and mice, it is not an optimal marker to distinguish these cells as it is
also expressed by activated T cells. IL2-Rα expression by Tregs correlates with the
requirement of IL-2 for their survival and expansion in the periphery. In contrast, IL-2
could be dispensable for their generation. In fact, Tregs from IL2-/- mice are reduced
in numbers but remain endowed with suppressive activity when transferred into wild-
type recipients. Tregs do not themselves produce IL-2 and rely on IL-2 that is
probably produced by effector cells. Thus, Tregs seem to be intimately linked to the
effector immune response that they regulate109-111. In fact, it was recently shown that
expression of the high affinity IL-2Rα by Tregs endows these cells with the capacity
to exploit the IL-2 resource and keeps Treg numbers tied to the number of activated
IL-2 producing CD4+T cells110.
A milestone in the study of CD25+ Tregs was the description of Foxp3, a forkhead
family of transcription factors specifically expressed by Tregs and considered to be
the master control gene for the development and function of natural Tregs112-114. In
mice Foxp3 is both necessary and sufficient for the development and function of
Tregs. Mice lacking functional Foxp3 develop a fatal autoimmune
lymphoproliferative disease and analyses of CD4+CD25+T cells from these mice
revealed that they lack suppressive activity, indicating that they do not represent
Tregs115. Foxp3 defective mice could be rescued by transferring wild-type
CD4+CD25+T cells. Furthermore, ectopic expression of Foxp3 in conventional
CD4+CD25-T cells by retro-virus mediated gene transfer conferred suppressor
function to this T cell subset both in vitro and in vivo112-114. These data clearly
indicated that in mice Foxp3 is an optimal marker for the identification of these cells
116. However, the human system was found to be much more complex and analysis of
Foxp3 expression showed several differences compared to the mouse system117.
Human FOXP3 exists in two isoforms, one of which is ortholog to mouse Foxp3. It is
unclear whether the 2 isoforms are expressed simultaneously and if there is a
functional difference between them118. In humans, Foxp3 is expressed by CD25+
Tregs but differently from mice it is also induced in all CD4+ T cell populations
following T cell activation. Whether Foxp3 expression in activated T cells correlates
with a suppressive activity is still controversial118, 119. Consistent with the idea that
Foxp3 in humans is linked to TCR stimulation, human CD4+ T cell clones were
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found to be Foxp3+, while expression of the protein was not detected in mouse T cell
clones117. Several groups have attempted to ectopically express Foxp3 in human
CD4+CD25-T cells, as was done in mouse cells, and this resulted in T cell hypo-
responsiveness and suppression of production of cytokines such as IL-2 and IFN- γ,
but did not seem to lead to acquisition of significant suppressive activity in vitro118.
Furthermore, a human syndrome was identified, IPEX (immune dysfunction,
polyendocrinopathy, enteropathy, X-linked syndrome), which presents clinical
features similar to those found in the Foxp3 deficient mice. Further analyses revealed
that a large proportion of the patients carried mutations in the gene encoding for
Foxp3.
How foxp3 is controlled and which signals induce its expression still remains elusive,
although some signalling pathways, including CD28, IL-2 and TGF-β are emerging
that appear to have an effect on the expression of foxp3117.
It is known that an initial activation of natural Tregs via the TCR is required for
suppression to occur, but the mechanism of suppression has been a controversial
point. Studies utilizing different experimental models lead to contrasting results with
major differences being observed between in vitro and in vivo models120. In vitro
suppression of Tregs seems to be totally dependent upon cell-contact mechanisms, as
suppression does not occur when cells are separated by a permeable membrane. In
contrast, in vivo experiments showed an essential role for cytokines such as IL-10 and
TGF-β120. Recent data using a T cell transfer model of colitis revealed an essential
role of TGF-β for Treg control of pathogenic effector cells, although surprisingly
TGF-β did not necessarily have to be synthesized from Tregs themselves, as Tregs
from TGF-β deficient mice were still functional and suppression remained TGF-β
dependent, suggesting a different cellular source of TGF-β121.
8.2. Adaptive T regulatory cells
An additional population of Tregs, called adaptive Tregs, was described to develop as
a consequence of activation of mature T cells in the periphery under particular
conditions of sub-optimal antigenic stimulation, such as with immature DCs or in the
presence of immunosuppressive drugs or cytokines IL-10 and TGF-β.
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A subset of adaptive T regulatory cells, designated T regulatory 1 cells, (Tr1),
producing IL-10, was described in both humans and mice. This subset was derived by
different groups by using different protocols, so it is still unclear whether and how
they are related to each other122-125.
Tr1 cells were first described by Roncarolo and co-workers who showed that chronic
activation of both human and murine CD4+T cells in the presence of IL-10, gave rise
to CD4+ T cell clones characterized by low proliferative capacity, production of high
levels of IL-10 and low levels of IL-2122, 123. TGF-β was also produced by these cells,
but at levels comparable to other T cell subsets. Human and murine Tr1 clones were
capable of suppressing the proliferation of CD4+T cells in vitro, in an antigen specific
manner. Furthermore, murine Tr1 cells, after stimulation in vivo, also prevented
colitis induced in SCID mice by pathogenic CD4+CD45Rbhigh splenic T cells. In both
human and murine systems, suppression of T cell proliferation was dependent upon
secreted IL-10 and TGF-β and was cell-contact independent.
Of note, Tr1 cells generated according to this protocol produce IL-10 but in addition
inflammatory cytokines such as IL-5 and IFN-γ.  Later reports by the same group
showed that Tr1 cells secreting IL-10 and IFN-γ could be generated by using IL-10 in
combination with IFN-α124.
By using a combination of the immunosuppressive drugs vitamin D3 (VitD3) and
dexamethasone (Dex), O’Garra and co-workers succeeded in generating an
homogeneous population of both human and mouse Tr1 cells, producing only IL-10
and no inflammatory cytokines such as IL-5 or IFN-γ125. Murine Tr1 cells generated
according to this protocol were capable of suppressing, in an IL-10 dependent
manner, experimental autoimmune encephalomyelitis (EAE) when activated at the
site of disease. Importantly, it was reported that Tr1 cells do not express Foxp3, and
are thus distinct from naturally occurring Tregs126.
Another subset of adaptive T regulatory cells was described in both mice and humans,
based on their ability to produce TGF-β and varying levels of IL-10 and IL-4. These
cells were termed Th3 cells, although it still remains unclear whether they are distinct
from Tr1 cells. Th3 cells were first described in mice after oral tolerance induction to
myelin basic protein (MBP). These cells were able to suppress experimental
autoimmune encephalomyelitis (EAE) via a TGF-β dependent mechanism127.
Generation of similar cells, endowed with the capacity to prevent autoimmune disease
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in several animal models was further reported 127-129. In vitro differentiation of Th3
cells was enhanced by TGF-β, IL-4 and IL-10130. Furthermore, in patients suffering
from multiple sclerosis, oral treatment with MBP and proteolipid protein (PLP)
induced a significant increase in the frequency of MBP- or PLP-T cells that secreted
TGF-β, suggesting that Th3 cells also exist in humans131. In this, as in many other
studies, TGF-β and IL-10 were not evaluated in parallel, thus making it difficult to
understand if Th3 and Tr1 cells represent distinct T regulatory subsets.
Several groups documented in the human system that adaptive T regulatory cells can
also be induced in the periphery by CD25+ Tregs via a cell-contact dependent effect,
mechanism which was termed “infectious tolerance”. The induced regulatory T cells,
which much resemble the described Tr1 cells, produce immunosuppressive cytokines
IL-10 and/or TGF-β and are able to suppress the activation of effector cells via a
cytokine dependent, cell-contact independent mechanism132, 133.
The existence of natural and adaptive T regulatory cells has been largely documented
but many questions remain open regarding their origin, mechanism of action and the
relations occurring between them.
The general characteristics of naturally occurring Tregs and adaptive Tregs are
summarized in Table 1.
Table 1. General characteristics of naturally occurring and adaptive Tregs.
In vitro: cell-contact
In vivo: cell-contact
     IL-10, TGF-β
     PositiveCD25+Thymus
(and periphery)
Naturally
occurring Tregs
   IL-10 and/or
        TGF-β
NegativeUnknownPeripheryAdaptive Tregs
(Tr1/Th3)
Mode of
suppressionFoxp3Phenotype OriginTreg type
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II. Results
1. Comments on manuscripts
1.1 Manuscript 1:
Heterogeneity of the CD4+T central memory pool
In this work we have dissected the human CD4+T central memory cell (TCM) pool,
and we have identified functionally distinct subsets of cells which are either
unpolarized or pre-committed to become TH1 (pre-TH1) and TH2 cells (pre-TH2).
Previous studies from our group reported that TCM cells, which constitutively express
the lymph node homing receptors CCR7 and CD62L, are largely devoid of effector
functions but acquire characteristics of effector memory cells (TEM) after stimulation
through the TCR or with homeostatic cytokines1, 2. Conversely, TEM cells have lost
expression of lymph node receptors but express chemokine receptors involved in
homing to inflamed tissues. Following TCR triggering, these cells rapidly produce the
effector cytokines IFN-γ, IL-4 or IL-5. Thus, in humans the CD4+TEM pool contains
bona fide TH1 and TH2 cells, which can be identified by their cytokine profile and
chemokine receptor expression. It was proposed that TCM cells represent a “stem cell
like” pool of antigen-primed cells, which migrate to secondary lymphoid organs and,
upon a secondary challenge, can rapidly generate new waves of antigen-specific
effector cells. In contrast, TEM cells can enter peripheral tissues and provide
immediate protection against invading pathogens2,3. Thus, understanding TCM cell
differentiation stage and potential is important for comprehending how TH1 and TH2
polarization is conserved from a primary response, and if it still maintains some
degree of flexibility in secondary immune responses.
Here we show that three chemokine receptors identify functional subsets within the
TCM pool. TCM cells expressing CXCR3 secrete low amounts of IFN-γ  whereas
CCR4+ TCM cells produce low amounts of IL-4 but not IL-5. Following expansion in
the presence of the homeostatic cytokines IL-7 and IL-15, these cells invariantly
differentiated to CCR7- cells that possessed the characteristics of TH1 and TH2 cells,
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suggesting that they represent cells which are pre-committed to give rise to TH1 (pre-
TH1) or TH2 cells (pre-TH2), respectively. Conversely, CXCR5+ TCM cells lacking
CXCR3 or CCR4 (CXCR5-/-) expression remained unpolarized following expansion
in homeostatic cytokines and retained lymph node homing potential (figure 3b).
Previous work has shown that CD4+T cells expressing CXCR5 comprise CCR7-
CD57+ follicular helper T cells in the tonsils4, 5, and the above mentioned,
unpolarized circulating CXCR5+T cells of unknown function and specificity, that
might have a recently activation history6. We show that CXCR5+ and CXCR5- cells,
lacking expression of CXCR3 or CCR4, display characteristics of cells that are at an
earlier stage of memory cell differentiation compared to pre-TH1 and pre-TH2 cells.
Furthermore, we observed that CXCR3+ and CCR4+ TCM cells maintained some
degree of flexibility following TCR stimulation in TH1 or TH2 condition, as they were
partially able to re-polarize to the opposite condition in the presence of the specific
cytokines. TH1 or TH2 polarizing cytokines did not have a similar effect if they were
added to cells stimulated with IL-7/IL-15 (figure 5). Similarly, CXCR5+ cells were
able to polarize to the TH1/TH2 direction in the presence of the specific cytokine,
following TCR triggering but not following IL-7/IL-15 stimulation. These results
suggested that following TCR triggering with polarizing cytokines, TCM cells maintain
a certain degree of flexibility of cytokine gene expression.
Unlike naïve T cells, all memory subsets displayed low T cell receptor rearrangement
excision circle content and spontaneously incorporated bromodeoxyuridine ex vivo,
indicating that they had divided in vivo to a similar extent and were undergoing a
slow turn over, under steady-state conditions. Furthermore, we observed that
pathogen-specific CD4+T cells had characteristic distributions within TCM and TEM
subsets, reflecting the TH1/TH2 polarization induced by the pathogen or vaccination.
Memory cells specific for vaccinia virus or cytomegalovirus, which typically promote
a TH1 response, were largely detected among CXCR3+ TCM and TEM cells. In contrast,
tetanus toxoid specific cells were detected among all subsets, consistent with the
notion that vaccination against tetanus induces a mixed TH1/TH2 response
7 (figure 6).
Altogether, these results show that cells in the TCM pool, identified by chemokine
receptor expression, are pre-committed to give rise to TH1 or TH2 cells, in
homeostatic conditions. Importantly, this could explain how the quality of primary T
cell responses is maintained in the absence of antigen. In contrast, upon a secondary
encounter with a given pathogen, memory cells may retain a certain degree of
38
flexibility and partially re-polarize to the opposite direction in the presence of the
appropriate polarizing conditions.
1.2. Manuscript 2:
Memory potential of antigen-primed CD4+T cells
The signals involved in selecting an activated T cell to survive and to generate a long-
lived memory T cell are still not completely understood. Previous work in mice
showed that in the absence of IL-7 no memory cells develop
8-11
, suggesting that IL-7
is required for the generation of memory cells. Furthermore, it was recently shown
that CD8+T memory precursors can be identified by expression of the IL7 receptor α
chain (IL-7R), early at the peak of the proliferative response
11, 12
. Nevertheless, IL7R
expression does not necessarily implicate that the T cell while survive and give rise to
a memory cell 
11, 13
. We therefore analysed the signal strength requirements for IL7R
expression on CD4+T memory cells and assessed their memory potential. We
observed that CD4+T cells expressing CCR7 and IL7R possessed a high capacity to
respond to IL-7 and to expand upon secondary TCR stimulation, therefore
representing good candidates for memory precursors. Following antigen encounter,
CCR7+IL7R
hi 
cells produced mainly IL-2, whereas CCR7-IL7R
lo 
identified effector
cells with higher death rates. Furthermore, we observed that the CCR7+IL7R
hi 
subset
included cells that varied in their memory potential, depending on the signal strength
they had received. In fact, CCR7+IL7R
hi 
cells that had received a weak stimulation
showed little or no responsiveness to IL-7 and possessed a high death rate. Cells
generated at an intermediate strength of stimulation proliferated slowly with IL-7 and
expanded efficiently upon secondary TCR stimulation, thus possessing characteristics
of unpolarized TCM cells. In contrast, strongly stimulated CCR7+IL7R
hi 
cells
expanded poorly upon TCR-engagement but displayed a high proliferative rate in the
presence of homeostatic cytokines (figure 3). In the latter conditions they
differentiated spontaneously to TH1 effector cells, a characteristic which is typical of
circulating CXCR3+ pre-TH1 cells (manuscript 1, figures 3 and 4). As IL7R
hi 
cells
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generated in the different stimulatory conditions displayed such diverse
responsiveness to IL-7, we analysed their capabilities of signalling through the
IL7R
14, 15
. We observed that, while the activities of the JAK kinases were similar,
those of s6-kinases correlated with IL-7 responsiveness and were dependent upon
signal strength. Consistently, the expression levels of PTEN, a phosphatase that
counteracts PI-3 kinase activity which in turn controls s6-kinase activity, was higher
in weakly stimulated compared to strongly stimulated cells (figure 4). To better
understand at a molecular level the observed differences in IL-7 responsiveness, we
performed gene expression analyses of CCR7+IL7R
hi 
cells generated by weak or
strong stimuli. We observed that cells that had received a strong stimulus were in a
higher metabolic state, expressed pro-apoptotic molecules and possessed lower
thresholds to cycle with mitogens. Furthermore, these cells expressed increased levels
of genes involved in TH1 deveolpment. These results are consistent with a TH1
commitment of these cells and their reduced survival following antigen encounter
(figure 5).
We conclude that the memory potential of CD4+T memory cells is dictated by the
strength of stimulation they receive, and is not necessarily predictable by phenotypic
markers. Our results are consistent with the view that T-cell memory is generated at
an intermediate range of signal strength and suggest that TCM and TEM subsets could
be derived from CCR7+ precursors that received different amounts of stimulation.
1.3 Manuscript 3:
 Characterization of IL-10 producing CD4+T memory cells
In this study we have addressed another aspect of CD4+T cell memory concerning the
maintenance of self-tolerance. We have identified a subset of IL-10 producing cells in
the CD4+T cell memory compartment characterized by the expression of the
chemokine receptor CCR6, and we investigated the mode of generation and
maintenance of these cells and the role they may play in the context of an immune
response.
Two major subsets of regulatory T cells have been described, naturally occurring
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Foxp3+CD25+Tregs and Tr1 cells, or IL-10 producing Tregs. Tr1 cells are
characterized by the capacity to produce IL-10 and inhibit immune responses in an
IL-10-dependent, cell-contact independent manner 
16-18
. It was shown that these cells
can be generated in vitro by tolerogenic priming with immature DC, IL-10 or
immune-suppressive drugs 
16, 19, 20
, but until now no surface markers that allow the
identification of Tr1 cells have been described. Naturally occurring CD25+Tregs are
also characterized by production of IL-10 although, at least in vitro, this cytokine does
not seem to play a role in the suppressive activity of Tregs. In fact, Treg suppression
of immune responses in vitro is dependent upon a still unclear cell-contact dependent
mechanism. Accumulated evidence suggests that both T regulatory subsets play an
important role in the control of autoimmune diseases
16
. Here we show that a
population of antigen-experienced CD4+ Foxp3-cells, distinct from natural Tregs and
characterized by expression of CCR6, secrete IL-10 in response to self-antigens and
inhibit autoreactivity in an IL-10-dependent manner (figure 4). We show that CCR6 is
induced in a tolerogenic environment, such as in the presence of IL-10 and TGF-β
(figure 1). Interestingly, both cytokines have been implicated in maintenance of self-
tolerance
21-23
. Cells specific for self-antigens in healthy donors are contained
exclusively within the CCR6+ population, while interestingly, cells with the same
specificities are also detected among CCR6- cells in patients affected by an
autoimmune pathology (figure 6). CCR6+T cells however, secrete IL-2 and
proliferate also in response to recall antigens. Thus, to investigate whether IL-10
producing self-reactive and IL-2 producing recall-antigen specific cells represented
distinct populations within CCR6+T cells, we analysed self-specific CCR6+T cells at
a single cell level. We performed single-cell cloning of autoreactive CCR6+T cells
which had undergone proliferation in the presence of autologous circulating mDCs
and obtained a certain number of clones displaying a similar behaviour. These clones
produced IL-10 and no IL-2 in the presence of autologous mDCs and proliferated
upon neutralization of IL-10. Interestingly, the same clones also proliferated
vigorously and produced IL-2 in the presence of the recall antigen tetanus toxoid
(figure 7). We propose a context dependent function of these CCR6+T memory cells,
in that they exhibit a Tr1-like suppressive capacity when exposed to self-antigens,
thus limiting autoimmune reactions, while in the presence of their specific antigen
41
they behave as memory cells and confer protection.
The mechanism described by us may represent a strategy evolved by the immune
system which allows the utilization of slightly autoreactive T cells, thus broadening
the TCR repertoire available for pathogen recognition, while lowering the risk of
autoimmune reactions. In fact, CCR6+T memory cells produce IL-10 upon encounter
of self-antigen, and may in this way raise their threshold for an autoimmune response.
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Abstract
 
We previously reported that central–memory T cells (T
 
CM
 
 cells), which express lymph node
homing receptors CCR7 and CD62L, are largely devoid of effector functions but acquire char-
acteristics of effector–memory T cells (T
 
EM 
 
cells) (i.e., CCR7
 
 
 
T helper [Th]1 or Th2 cells) after
stimulation with T cell receptor agonists or homeostatic cytokines. Here we show that three
chemokine receptors identify functional subsets within the human CD4
 
 
 
T
 
CM 
 
cell pool. T
 
CM
 
cells expressing CXCR3 secreted low amounts of interferon 
 

 
, whereas CCR4
 
 
 
T
 
CM 
 
cells pro-
duced some interleukin (IL)-4, but not IL-5. In response to IL-7 and IL-15, CXCR3
 
 
 
T
 
CM 
 
and
CCR4
 
 
 
T
 
CM 
 
cells invariably generated fully differentiated CCR7
 
 
 
Th1 and Th2 cells, respectively,
suggesting that they represent pre-Th1 and pre-Th2 cells. Conversely, CXCR5
 
 
 
T
 
CM 
 
cells
lacking CXCR3 and CCR4 remained nonpolarized and retained CCR7 and CD62L expression
upon cytokine-driven expansion. Unlike naive cells, all memory subsets had a low T cell re-
ceptor rearrangement excision circle content, spontaneously incorporated bromodeoxyuridine
ex vivo, and contained cells specific for tetanus toxoid. Conversely, recall responses to cyto-
megalovirus and vaccinia virus were largely restricted to CXCR3
 
 
 
T
 
CM 
 
and T
 
EM 
 
cells. We conclude
that antigen-specific memory T cells are distributed between T
 
EM 
 
cells and different subsets of
T
 
CM 
 
cells. Our results also explain how the quality of primary T cell responses could be maintained
by T
 
CM 
 
cells in the absence of antigen.
Key words: T cell subsets • memory maintenance • cytokines • differentiation • 
chemokine receptors
 
Introduction
 
Upon recognition of antigenic peptides on DCs, naive T
lymphocytes proliferate and differentiate into a variety of
effector cells depending on the stimulatory conditions and
cytokine milieu (1, 2). Accumulating evidence indicates
that during the T cell differentiation process, effector func-
tions and homing potentials are coordinately regulated (3).
For instance, developing Th1 cells acquire the capacity to
produce IFN-
 
 
 
and expression of chemokine receptors
such as CCR5, CXCR3, and CXCR6 that drive them to
sites of delayed-type hypersensitivity reactions. Conversely,
developing Th2 cells acquire the capacity to produce IL-4
and express CCR3, CCR4, CCR8, and the prostaglandin
D2 chemoattractant receptor CRTh2 (4–7), which are re-
quired to migrate at sites of allergic reactions (6, 8, 9).
Expression of the lymph node homing receptors CCR7
and CD62L (10, 11) has been used to define subsets of human
memory T cells with distinct functional properties. T cells
within the CCR7
 
 
 
“central–memory” T cell (T
 
CM 
 
cell)
cell subset show hypo-acetylated cytokine genes and have
no or low effector functions, but efficiently differentiate to
Th1 or Th2 effector cells after TCR stimulation in the
presence of IL-12 or IL-4, respectively (12–14). In contrast, T
cells of the CCR7
 
 
 
“effector–memory” T cell (T
 
EM 
 
cell)
subset show polarized cytokine gene acetylation patterns in
vivo and rapidly produce high amounts of IFN-
 
 
 
and IL-4
upon antigenic stimulation (12–14). It has been proposed
that in secondary immune responses, T
 
CM 
 
cells generate
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new waves of effector cells in antigen-draining lymph
nodes, whereas T
 
EM 
 
cells provide immediate protection
against invading pathogens in peripheral tissues (3, 14).
The maintenance of T cell memory is controlled by cy-
tokines that promote cell survival and slow homeostatic
proliferation (15). In particular, IL-7 and IL-15 have been
shown to regulate mouse CD8
 
 
 
memory T cell survival
and self-renewal in the absence of antigen (16, 17), whereas
naive and CD4
 
 
 
memory cells require IL-7 and TCR
ligands (16, 18, 19), but do not respond to IL-15 (17).
Conversely, human CD4
 
 
 
memory T cells proliferate in
response to IL-15 in a TCR-independent fashion and with
slow kinetics (20, 21), suggesting different roles for IL-15
in mouse and human CD4
 
 
 
memory T cell homeostasis.
Notably, T
 
CM 
 
cells proliferating in response to IL-7 and IL-
15 differentiate and generate Th1 and Th2 effector cells
(21), but how uncommitted T
 
CM 
 
cells proliferating in the
absence of antigen could maintain the quality of the pri-
mary response remained unclear.
The existence of T
 
CM 
 
and T
 
EM 
 
cell subsets has also been
documented in mice (22, 23). In this experimental system,
it has been possible to directly examine the kinetics of
memory cell generation and the capacity of effector and
memory subsets to reconstitute long-term memory (24),
and there is growing evidence that T
 
CM 
 
cells have higher
reconstitution potential (24, 25). In particular, effector Th1
cells, defined by their secretion of IFN-
 

 
, were found to be
short-lived and unable to reconstitute T cell memory. In
contrast, a population of activated Th1 lineage cells, which
did not secrete IFN-
 
 
 
after primary antigenic stimulation,
persisted for several months in vivo and developed the ca-
pacity to secrete IFN-
 
 
 
upon subsequent stimulation (26).
Since the first description of T
 
CM 
 
and T
 
EM 
 
cells, it was
evident that other chemokine receptors, as well as adhesion
and costimulatory molecules, are expressed on different
fractions of T
 
CM 
 
cells (12, 14). Heterogeneity of human
CD4
 
 
 
T
 
CM 
 
cells has further been documented using CXCR5,
the receptor for CXCL13, a chemokine expressed in B cell
follicles (27, 28). CXCR5
 
 
 
T
 
CM 
 
cells lacked effector func-
tions and cells specific for tetanus toxoid (TT), but con-
tained residual T cell receptor rearrangement excision
circles (TRECs), suggesting that they represent recently
activated cells (29–31). Conversely, other recent studies
claimed that both T
 
CM 
 
and T
 
EM 
 
cells possess high levels of
effector functions, and that consequently neither CCR7
nor CXCR5 expression identify nonpolarized CD4
 
 
 
mem-
ory T cells (9, 32–35). Understanding T
 
CM 
 
cell differen-
tiation stage and potential is of importance for the ho-
meostatic maintenance of memory T cells and for the
conservation of T cell polarization in secondary responses.
Here we report that CXCR3 and CCR4 identify two
novel subsets of pre-Th1 and pre-Th2 cells within T
 
CM
 
cells. These cells possessed low IFN-
 

 
–
 
 
 
or IL-4–producing
capacities when compared with CXCR3
 
 
 
and CCR4
 

 
T
 
EM 
 
cells and spontaneously differentiated to Th1 and Th2
effector cells in response to homeostatic cytokines IL-7 and
IL-15 independently of conventional Th1 or Th2 cell–induc-
ing stimuli. In contrast, T
 
CM 
 
cells lacking CXCR3 or CCR4
and expressing CXCR5 were nonpolarized cells whose dif-
ferentiation to Th1 or Th2 cells is dependent on TCR trig-
gering and signaling by polarizing cytokines.
 
Materials and Methods
 
Cell Culture.
 
PBMCs were isolated from buffy-coated blood
from healthy donors. Monocytes were depleted by adhesion for
30 min and CD4
 
 
 
T cells were isolated by negative selection
with magnetic beads using Automacs (Miltenyi Biotec). Memory
T cells were isolated by further depletion of naive T cells with
anti-CD45RA beads (Miltenyi Biotec). Memory T cell subpopu-
lations were purified to 
 

 
95% by cell sorting after five-color
staining as follows: anti-CXCR5 (R&D Systems) followed by
anti-IgG2b PE (Biosystems), anti-CCR7 (R&D Systems) fol-
lowed by anti-IgG2a FITC (Biosystems), and anti-CXCR3 Cy-
Chrome, anti-CD45RA APC, and anti-CCR4 biotin followed
by streptavidin-APC-Cy7 (BD Biosciences). Labeling of T cells
with carboxyfluorescein succinimidyl ester (CFSE) was performed
as described previously (21). Monocytes were purified by positive
selection with anti-CD14 beads (Miltenyi Biotec). For DC dif-
ferentiation, CD14
 
 
 
cells were cultured for 4 d in complete me-
dium (RPMI 1640 supplemented with 2 mM glutamine, 1%
nonessential amino acids, 1% sodium pyruvate, 50 
 

 
g/ml kana-
mycin, 50 U/ml penicillin, and 50 
 

 
g/ml streptomycin; GIBCO
BRL) containing 10% FCS (Hyclone), 50 ng/ml granulocyte/
macrophage colony-stimulating factor (Novartis), and 1,000
U/ml IL-4. The DCs obtained were stimulated for 24 h with 100
ng/ml lipopolysaccharide (
 
Salmonella
 
 
 
abortus equi
 
; Sigma-Aldrich)
and pulsed for 30 min with 100 ng/ml toxic shock syndrome
toxin (TSST). CFSE-labeled 5 
 
 
 
10
 
4 
 
T cells were cultured with
TSST-pulsed DCs in flat-bottom wells at a 5:1 ratio, and recom-
binant cytokines were used at either 25 ng/ml (IL-7 and IL-15;
R&D Systems), 10 ng/ml (TNF, IL-6, IL-10, IL-4, and IL-12;
BD Biosciences), or 1,000 U/ml (IL-2; Roche), whereas neutral-
izing antibodies to IL-4 and IL-12 (BD Biosciences) were used at
2 
 

 
g/ml.
 
ELISA, Intracellular Cytokine Staining, and IFN-
 
 
 
Secretion Assay.
 
Cytokine-producing capacity of FACS-purified subsets was as-
sessed after stimulation of purified cell populations at 5 
 
 
 
10
 
4
 
/100
 

 
l for 24 h with 50 nM phorbol-12-13-dibutyrate (PdBu) and 0.5
 

 
g/ml ionomycin, or in wells coated with 2 
 

 
g/ml each of anti-
CD3 (clone TR66) and anti-CD28 antibodies (BD Biosciences).
Cytokine concentrations of supernatants were then assessed by
ELISA according to a standard protocol and analyzed with the
Softmax program. Intracellular IFN-
 
 
 
was detected after stimulat-
ing cells in the presence of 10 
 

 
g/ml brefeldin A (Sigma-Aldrich)
for the last 2 h and after fixation with paraformaldehyde and per-
meabilization with saponin. After saturation of nonspecific bind-
ing sites with 10% FCS, cells were incubated with APC-labeled
antibody to IFN-
 
 
 
and PE-labeled antibody to IL-2 or IL-4 (BD
Biosciences), washed, and analyzed by flow cytometry on a
FACSCalibur with CELLQuest software (Becton Dickinson). To
sort live IFN-
 

 
–producing cells, we stimulated cells for 60 h with
25 ng/ml cytokines (IL-7, IL-15, IL-12, TNF-
 

 
, and IL-18), and
IFN-
 

 
–producing cells were identified with an IFN-
 
 
 
secretion
assay kit (Miltenyi Biotec) and purified by cell sorting.
 
Recall Responses.
 
PBMCs from 50 ml of fresh blood from
healthy volunteers were prepared, monocytes were isolated and
either incubated for 16 h with a replication-deficient vaccinia vi-
rus (VV; provided by G. Sutter, Institute for Virology, Munich,
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Germany) or left untreated. 5 
 
 
 
10
 
4 
 
monocytes were then irradi-
ated and incubated in the absence or presence of 1 
 

 
g/ml TT or
2.5 
 

 
g of an extract of CMV-derived proteins (provided by R.
Campanelli, University of Pavia, Pavia, Italy) with purified T cell
subsets at a 1:1 ratio in U-bottom wells in complete medium con-
taining 5% human serum. On days 5 and 7, cells were stained for
CD14 and CD4, and CFSE dilution of CD4
 
 
 
CD14
 
 
 
viable cells
was assessed by flow cytometry. On day 5, cells had not yet di-
luted CFSE completely, and the precursor frequency of antigen-
specific cells could therefore be calculated as described previously
(36). In some experiments, the presence of pathogen-specific cells
was confirmed by restimulating cells with autologous monocytes
treated as described above followed by assessment of cytokine pro-
duction of proliferating T cells by intracellular staining.
 
Ex Vivo Bromodeoxyuridine (BrdU) Labeling.
 
The assay was
performed as described previously (25). In brief, fresh PBMCs
were cultured with 10 
 

 
g/ml BrdU (Sigma-Aldrich) for 16 h.
CD4
 
 
 
cells were then positively selected with anti-CD4 mag-
netic beads and stained for CD45RA and chemokine receptor
expression. Cells were then fixed, permeabilized, treated with
DNase (Boehringer), stained with FITC-labeled anti-BrdU anti-
body (Becton Dickinson), and analyzed by flow cytometry.
 
Quantitative PCR of TRECs.
 
Memory CD4
 
 
 
T cells were
isolated by MACS as described above, stained for CD4,
CD45RO, CCR7, and CXCR5, and sorted to 
 

 
99.9% purity.
Quantification of signal joint TRECs in sorted CD4
 
 
 
T cell sub-
sets was performed by real-time quantitative PCR with the 5
 

 
nuclease (TaqMan) assay using an ABI 7700 sequence detector
(Applied Biosystems). As described previously (37), 1–2 
 
 
 
10
 
5
 
cells were lysed in 10 mM Tris, pH8, containing 100 
 

 
g/ml of
proteinase K (GIBCO BRL) for 2 h at 56
 
	
 
C, and then for 15 min
at 95
 
	
 
C. PCR reaction of lysates was performed with 500 nM of
primers (CACATCCCTTTCAACCATGCT and GCCAGCT-
GCAGGGTTTAGG) and 125 nM of probe FAM-ACAC-
CTCTGGTTTTTGTAAAGGTGCCCACT-TAMRA. PCR
conditions were as follows: 1 cycle of 2 min at 50
 
	
 
C, 1 cycle of
10 min at 95
 
	
 
C, followed by 40 cycles of 30 s at 95
 
	
 
C, and 1 min
at 65
 
	
 
C. Levels of DNA were standardized by normalizing with
18S rRNA sequences.
 
Results
 
Subsets of Human CD4
 
 
 
T
 
CM 
 
Cells Identified by Expression
of CXCR5, CXCR3, and CCR4.
 
Purified human CD4
 

 
T cells were analyzed for chemokine receptor expression by
five-color staining. CD45RA
 
 
 
cells expressed CCR7, but
were largely negative for the other chemokine receptors,
consistent with the view that they are predominantly anti-
gen-inexperienced “naive” T cells (not depicted). Con-
versely, the following three main subsets could be identified
in CD45RA
 
 cells according to CCR7 and CXCR5
expression: CXCR5 CCR7 cells (CXCR5 TCM),
CXCR5 CCR7 cells (CXCR5 TCM), and CXCR5
CCR7 cells (TEM; Fig. 1 A). Within these main subsets,
staining with antibodies to CXCR3 and CCR4 revealed
further heterogeneity (Fig. 1 B). CXCR3 and CCR4 were
expressed on different populations of TEM cells, which
contain Th1 and Th2 effector cells (4, 9, 38). However,
CXCR3 and CCR4 were also expressed on some TCM cells,
especially within the CXCR5 subset (Fig. 1 B). Thus, the
following four major subsets of TCM cells were identified: (a)
CXCR3 CCR4 CXCR5 TCM cells (“CXCR5 TCM”),
(b) CXCR3 CCR4 CXCR5 TCM cells (“
 TCM”), (c)
CXCR5 CXCR3 CCR4 TCM cells (“CXCR3 TCM”),
and (d) CXCR5 CCR4 CXCR3 TCM cells (“CCR4
TCM”). Mean values  standard deviations of the four sub-
sets in four healthy donors were 11  5%, 18  10%, 17 
8%, and 17  12%, respectively.
Because CXCR3 and CCR4 have been associated with
differentiated Th1 and Th2 cells (7, 38), we analyzed ex-
pression of other surface markers that are acquired or lost
Figure 1. Expression of chemokine receptors defines
CD4 TCM cell subsets with distinct replicative potentials.
Purified CD4 T cells were stained with antibodies specific
for CXCR5, CCR7, CXCR3, CCR4, and CD45RA,
and analyzed by five-color flow cytometry. (A) CCR7 and
CXCR5 expression of CD45RA cells of one representative
donor out of four. (B) CXCR5 TCM, CXCR5 TCM, and
TEM cells were analyzed for CXCR3 and CCR4 expression.
Percentages indicate the mean frequency of subsets in the
memory pool of five healthy donors. (C) Purified, CFSE-
labeled CD4 T cell subsets were stimulated with IL-7 and
IL-15, or TSST-loaded DCs for 7 d. CFSE profiles of viable
(propidium iodide) cells were analyzed by flow cytome-
try. Numbers in the top row indicate the percentage of
dividing cells and numbers in parenthesis indicate the
mean division number. Numbers in the bottom row indi-
cate the fraction of TSST-responsive TCR V2 cells.
One representative donor out of four is shown.
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with T cell differentiation (12, 17, 39; Table I). As
expected, naive T cells expressed uniformly CD27 and
CD62L, but not the IL-2/15R chain (CD122), whereas
most TEM cells had lost CD27 and CD62L expression, but
were CD122. CXCR5 TCM cells had a phenotype simi-
lar to naive cells, whereas CXCR5 TCM cells expressed in-
termediate levels of CD27, CD62L, and CD122. In partic-
ular, CXCR3 TCM cells were CD122 and had partially
lost CD62L expression, consistent with a more differenti-
ated phenotype. The differences in CD122 expression
were functionally relevant because they closely correlated
with proliferation in response to IL-7 and IL-15 (Fig. 1 C,
top), being low in naive cells and CXCR5 TCM cells, in-
termediate in CCR4 TCM cells and /TCM cells, and high
in CXCR3 TCM and TEM cells.
We then compared the expansion potential of purified
CFSE-labeled CD4 naive and memory T cell subsets after
TCR stimulation with TSST-loaded DCs because replica-
tive capacity diminishes with T cell differentiation (25, 40).
Proliferation and accumulation was high in naive cells,
CXCR5 TCM cells, and /TCM cells, intermediate in
CCR4 and CXCR3 TCM cells, and low in TEM cells (Fig.
1 C, bottom). As reported for the CD8 compartment (25),
the reduced accumulation of TEM cells was associated with
a high rate of apoptosis (Table I). Similar results were ob-
tained upon stimulation with anti-CD3 and anti-CD28 an-
tibodies (not depicted).
Together, these results show that subsets of CD4 TCM
cells identified by CXCR5, CXCR3, and CCR4 expres-
sion differ in their proliferative response to cytokines and
TCR ligands, and suggest that CXCR5 TCM cells and
/TCM cells are at an early stage of memory cell differenti-
ation, whereas CCR4 and CXCR3 TCM cells have char-
acteristics of more mature cell types.
CXCR3 and CCR4 Identify TCM Cells with Low IFN-–
and IL-4–producing Capacities. Next, we analyzed effector
cytokine–producing capacities of TCM and TEM cell sub-
sets. Total TCM and TEM cell populations were sorted for
CXCR3 and CCR4 expression, stimulated with PdBu and
ionomycin, and secreted cytokines were quantified by
ELISA (Fig. 2 A). TCM cells lacking CXCR3 and CCR4
failed to produce IFN-, IL-4, and IL-5, whereas double
negative cells in the TEM subset produced all three cyto-
kines. Consistent with the role of CXCR3 and CCR4 as
Th1 and Th2 cell markers, CXCR3-expressing cells pro-
duced predominantly IFN-, whereas CCR4 cells pro-
Table I. Expression of CD27, CD62L, and IL-2/IL-15R Chain (CD122) on Naive T Cells and Memory T Cell Subsetsa
TCM
CXCR5 CXCR5
TN 
 CXCR3 
 CCR4 TEM
CD27 (%)b 99  1 98  2 76  9 83  9 72  17 40  8
CD62Lhi (%)b 99  1 89  5 55  15 84  8 79  9 23  12
CD122 (MFI)c 1  1 3  2 8  3 6  2 5  2 10  3
PI (%)d 3  2 7  4 17  9 9  5 15  8 25  10
aMean  standard deviation of four healthy donors.
bPercent of positive cells.
cMean fluorescence intensity.
dPropidium iodide cells after stimulation for 3 d with DC TSST.
Figure 2. Ex vivo cytokine-producing capacities of CD4 memory T
cell subsets. (A) Purified CD4 TCM and TEM cell subsets were stimulated
with PdBu and ionomycin for 24 h and supernatants were analyzed for
IFN- (diluted 1:4, white bars), IL-4 (black bars), and IL-5 (gray bars) by
ELISA. Stimulation with anti-CD3 and anti-CD28 antibodies gave similar
results (not depicted). Shown is the mean of four experiments with cells
from different donors. (B) CXCR3 CD4 T cells were sorted for CCR7
and CD62L expression as indicated and IFN- production was assessed as
described above. The mean of three independent experiments with three
different donors is shown.
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duced mainly type 2 cytokines. However, CXCR3 TCM
and CCR4 TCM cells produced less effector cytokines
than the corresponding TEM cell subset, and IL-5 produc-
tion was entirely restricted to TEM cells. Similar results were
obtained when CXCR5 TCM and CXCR5 TCM cell
subsets were analyzed separately (not depicted). Because
CXCR3 TCM cells contained a considerable fraction of
CD62L cells (Table I), we further analyzed IFN-–pro-
ducing capacity of CXCR3 TCM and TEM cells according
to CD62L expression (Fig. 2 B). CXCR3 TCM cells ex-
pressing CD62L produced only low amounts of IFN-,
whereas CXCR3 TCM cells lacking CD62L produced
high levels of IFN- comparable to TEM cells. Thus, IFN-
production among CCR7 cells is largely restricted to a
TEM cell–like subset of CD62L CXCR3 cells. Collec-
tively, these results show that CXCR3 and CCR4 identify
cells in the TCM cell pool that are nonpolarized or produce
low levels of IFN- or IL-4.
Cytokine-stimulated CXCR3 and CCR4 TCM Cells Dif-
ferentiate to Th1 and Th2 Cells. We previously showed
that some cytokine-stimulated TCM cells spontaneously dif-
ferentiate to Th1 or Th2 cells, whereas naive cells require
TCR ligands or inflammatory cytokines for differentiation
(21, 41). To understand whether the subsets defined by
CXCR5, CXCR3, and CCR4 could discriminate cells
with predetermined fates, we induced proliferation of puri-
fied CD4 T cell subsets by either TSST-loaded DCs or
IL-7 and IL-15 (Fig. 3 A). Because memory subsets showed
different proliferative responses to IL-7 and IL-15 (Fig. 1
C), and acquisition of effector cytokine–producing capaci-
ties progressively increases with division number (42, 43),
analysis was performed by gating on cells that had per-
formed the same number of divisions (cytokines: 4; TSST:
7). Under both conditions of stimulation, CXCR5 TCM
cells that lacked CXCR3 and CCR4 expression remained
nonpolarized, whereas /TCM cells generated some Th1
and Th2 cells and acquired CXCR3 and CCR4 on a frac-
tion of cells at the same time (Fig. 3 C). Cytokine-stimu-
lated CXCR5 TCM cells progressively lost CXCR5 ex-
pression, but homogeneously maintained high levels of
CCR7 and CD62L, whereas a fraction of CXCR5 TCM
cells progressively lost CCR7 and CD62L expression, thus
acquiring the phenotype of TEM cells (Fig. 3 B). Notably,
TEM cells remained CCR7 and maintained high effector
functions under these conditions.
When CXCR3 TCM and CCR4 TCM cells were
expanded with homeostatic cytokines, they maintained
CXCR3 and CCR4 expression (Fig. 3 C) and spontane-
ously differentiated into Th1 and Th2 cells, respectively
(Fig. 3 A). Thus, CCR4 TCM cells produced high levels of
IL-4 and also secreted IL-5 (not depicted), a type 2 cyto-
kine produced exclusively by TEM cells (Fig. 2 A). More-
over, the amount of IFN- produced by CXCR3 TCM
cells stimulated with IL-7 and IL-15 was comparable to
that produced by CXCR3 TEM cells ex vivo, and a frac-
tion of CXCR3 TCM cells acquired expression of CCR5
(Fig. 3 C), a receptor for inflammatory chemokines ex-
pressed on Th1 effector cells (5). Together, these results
demonstrate that TCM cells that lack CXCR3 and CCR4
expression are nonpolarized precursors, whereas CXCR3
and CCR4 TCM cells represent pre-Th1 and pre-Th2 cells
that become fully differentiated Th1 and Th2 effector cells
in response to homeostatic cytokines.
Figure 3. (A) Differentiation of TCM cell subsets in response to TCR or
cytokine stimulation. Purified CD4 T cell subsets were CFSE labeled
and stimulated with TSST-loaded DCs or with IL-7 and IL-15 in the
presence of neutralizing anti–IL-4 and anti–IL-12 antibodies. After 7 d,
cells were stimulated with PdBu and ionomycin, stained with APC-labeled
anti–IFN- and PE-labeled anti–IL-4 antibodies, and cells of the same divi-
sion number were analyzed by flow cytometry. Unstimulated T cell subsets
were also analyzed ex vivo as control. Numbers indicate the percentage of
cells producing IFN- or IL-4. One respresentative experiment out of
five is shown. (B and C) Modulation of homing receptor expression by
cytokine-stimulated CD4 memory T cell subsets. Purified CFSE-labeled
CD4 T cell subsets were stimulated with IL-7 and IL-15. TCM and TEM
cells in B were sorted for CXCR5, CCR7, and CD62L expression,
whereas in C they were sorted for CXCR5, CCR7, CXCR3, and
CCR4 expression as indicated. After 7 d, cells in division four were analyzed
for the expression of CXCR5, CCR7, and CD62L (B), or CXCR3,
CCR4, and CCR5 (C). One representative donor out of four is shown.
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To exclude a selective outgrowth of preexisting IFN-–
producing cells from CXCR3 TCM cells, we wished to
deplete cells with IFN-–producing capacity from cyto-
kine-stimulated cultures. To this aim it was necessary to
induce IFN- production of Th1 cell–polarized memory
cells without activating TCR-dependent signaling. It is
well established that TCR-independent IFN- production
of activated Th1 cells can be induced by inflammatory cy-
tokines IL-12 and IL-18 (44, 45). We found that produc-
tion of IFN- by resting CD4 memory cells in response
to IL-12 and IL-18 required activation by IL-7 and IL-15,
was boosted by TNF-, and occurred with delayed kinet-
ics (Fig. 4 A). In contrast, IL-2 production was restricted
to TCR-stimulated cells (not depicted), confirming that
IFN- production by cytokine-stimulated cells is TCR in-
dependent. Notably, TCR and cytokine stimulation in-
duced a similar fraction of cells to secrete IFN- before cell
division (Fig. 4 A, note empty/filled symbols), and IFN-
production was in both cases restricted to CXCR3 TCM
and TEM cells (Fig. 2 and not depicted). Thus, mature Th1
cell–polarized memory cells can be identified by IFN- se-
cretion after either TCR or optimal cytokine activation.
Next, we induced IFN- production by purified CFSE-
labeled CXCR3 TCM cells with cytokines, sorted undi-
vided IFN- cells after 60 h, expanded them with IL-7 and
IL-15, and analyzed effector cytokine–producing capacities
of proliferating cells (Fig. 4 B). A large fraction of IFN-
CXCR3 TCM cells differentiated under these conditions
and acquired the capacity to produce high levels of IFN-.
Sorting IFN- cells after 72 h gave similar results (not de-
picted). In contrast, CCR4 TCM cells secreted IL-4 under
the same conditions, whereas IFN- CXCR3 TCM cells
maintained high IFN- production. We conclude that
CXCR3 TCM cells lacking IFN-–producing capacity be-
come Th1 effector cells after TCR-independent prolifera-
tion induced by cytokines.
Figure 4. (A) Kinetics and requirements of TCR- and cytokine-induced
IFN- production. CFSE-labeled CD4 memory T cells were stimulated
for the indicated times with either anti-CD3 and anti-CD28 antibodies
(squares), or with TNF-, IL-12, and IL-18 in the absence (circles) or
presence (triangles) of IL-7 and IL-15. IFN- production was analyzed by
intracellular staining. Empty symbols indicate conditions with undivided
cells, whereas filled symbols indicate conditions with dividing cells. The
mean percentage of IFN- cells of three independent experiments is plot-
ted. (B) Cytokine-stimulated CXCR3 TCM cells lacking IFN-–producing
capacity become Th1 cell effector cells. Purified CFSE-labeled CXCR3
TCM and CCR4 TCM cells were stimulated with IL-7, IL-15, TNF-,
IL-12, and IL-18 for 60 h, and IFN-–secreting cells were purified by cell
sorting. IFN- and IFN- cells were then expanded for an additional
5 d with IL-7 and IL-15, briefly stimulated with PdBu and ionomycin, and
analyzed for IL-4 and IFN- production by intracellular staining. One rep-
resentative donor out of three is shown.
Figure 5. Effects of polarizing cytokines on TCR- and
cytokine-induced differentiation. Purified CFSE-labeled
CD4 T cell subsets were stimulated with DC plus TSST
or IL-7 plus IL-15 in the absence or presence of IL-12 and
neutralizing anti–IL-4 antibody (Th1-condition) or IL-4
and neutralizing anti–IL-12 antibody (Th2-condition). After
7 d, cells were stimulated with PdBu and ionomycin and
cells of the same division number were analyzed for IFN-
and IL-4 production by intracellular staining. The percent-
ages of INF- cells (white bars), IL-4 cells (black bars),
and of cells producing both cytokines (gray bars) are repre-
sented. One representative experiment out of five with
different donors is shown.
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We then analyzed the effects of polarizing cytokines on
T cell differentiation induced by TCR agonists or homeo-
static cytokines. IL-4 and IL-12 induced differentiation
of TCR-stimulated CXCR5 and especially /TCM
cells into IL-4– and IFN-–producing cells, respectively,
whereas they failed to modulate T cell differentiation in
IL-7 plus IL-15–activated T cells (Fig. 5, A and B). Under
the same conditions of TCR stimulation, IL-4 induced
CXCR3 T cells to produce the opposite cytokine IL-4
and promoted CCR4 expression, whereas IL-12 induced
CCR4 cells to produce IFN- (Fig. 5 A) and up-regulate
CXCR3 (not depicted). Again, polarizing cytokines had
little effect on the extent of T cell differentiation in IL-7
plus IL-15–stimulated cells (compare Figs. 3 A and 5 B).
Similar results were obtained when IL-2 substituted for
IL-7 and IL-15, and in the absence or presence of TNF,
IL-6 and IL-10, DC-derived cytokines that strongly boost
proliferation of TCM cells in response to IL-7 and IL-15
(not depicted; reference 21). Together, these findings sug-
gest that flexibility of cytokine gene expression of human
memory T cells requires TCR triggering and polarizing
cytokines (13).
Proliferation History, In Vivo Turnover, and Recall Responses
of CD4 Memory T Cell Subsets. The proliferation his-
tory and in vivo turnover of the different memory T cell
subsets was then assessed by measuring the amounts of
TRECs and the spontaneous BrdU incorporation of ex
vivo–isolated cells. TRECs carrying a particular signal
joint sequence (37) were quantified by TaqMan PCR in T
cell subsets from five healthy donors (Fig. 6 A). As ex-
pected, CD4 CD45RA naive T cells contained high
levels of TRECs, whereas B cells and T cell clones were
negative (not depicted). Compared with naive T cells,
CXCR5 TCM and CXCR5 TCM cells contained much
lower amounts of TRECs, whereas TEM cells contained
the lowest amount. Although there were considerable
quantitative differences among individual donors, these
data indicate that the different subsets of TCM cells have di-
vided to a similar extent.
To measure the spontaneous BrdU incorporation, freshly
isolated PBMCs were incubated with BrdU. CD4 T cells
were then purified and T cell subsets analyzed by intracellu-
lar staining with anti-BrdU antibodies. As shown in Fig. 6
B, CXCR5 TCM, CXCR3 TCM, and CCR4 TCM cells
spontaneously incorporated BrdU to a similar extent,
whereas TEM and especially /TCM cells had a higher prolif-
eration rate and naive cells were below the detection limit.
These data indicate that memory T cells in different subsets
slowly turn over under steady-state conditions in vivo.
To investigate whether the different memory subsets
contained cells specific for recall antigens, T cell popula-
tions were isolated from smallpox- and/or tetanus-vacci-
nated donors and stimulated for 7 d with autologous
monocytes that were incubated with TT or with an extract
of CMV-derived proteins. To assess memory against small-
pox, monocytes were infected with a replication-deficient
VV. In these experiments, purified CFSE-labeled T cell
subsets and CFSE dilution were used to read out prolifera-
tion of pathogen-specific T cells. From eight donors ana-
lyzed, seven responded strongly to TT, whereas one donor
that had been boosted 20 yr ago had a low response (not
depicted). Five donors responded strongly to CMV, and
four of six donors that had also been vaccinated against
smallpox had a detectable response to VV. Responses to
autologous monocytes alone were undetectable or very
low (not depicted).
We analyzed the distribution of TT-, CMV-, and VV-
specific T cells among different memory subsets (one donor
Figure 6. Proliferation history, in vivo turnover, and recall responses of
CD4 memory T cell subsets. (A) Total CXCR5 TCM, CXCR5 TCM,
and TEM cells were analyzed for their single joint TREC content and
compared with naive cells from the same donor (naive cells: 100%). Bars
indicate the mean TREC levels in memory subsets of five different donors.
(B) Freshly isolated PBMCs were incubated with BrdU, CD4 T cells
were isolated, and BrdU incorporation was analyzed as a function of
CD45RA and chemokine receptor expression by flow cytometry. The
mean percentage of BrdU cells in a given subset of four donors is shown.
(C) CD4 naive and memory subsets were sorted, labeled with CFSE,
and incubated with autologous monocytes that had either been infected
with VV or incubated with TT or an extract of CMV-derived proteins.
CFSE profiles of viable CD4 CD14 cells on day 7 of one representative
donor are shown. (D) Recall responses of memory subsets to TT of eight
different donors were assessed as described above, and the frequency of
TT-specific cells was calculated after 5 d. The frequency of TT-specific
cells in the indicted memory subsets of seven different TT-responsive donors
was plotted against the time of the last boost.
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responding to all three pathogens is shown in Fig. 6 C). In
all cases, pathogen-specific cells were detected in both the
TCM and TEM cell pools. TT-specific cells were undetect-
able among naive cells, but present in all memory subsets in
six of seven responsive donors. Conversely, CMV-specific
cells were largely restricted to CXCR3 TCM and TEM cells
in all five responsive donors, consistent with the notion
that CMV infection promotes a Th1 cell response (46).
Consistent with previous reports, VV-specific cells were
less frequent (47, 48), but were detectable in CXCR3
TCM and TEM cells and, interestingly, in three of four do-
nors in CXCR5 TCM cells. Together, these results show
that all memory subsets contain cells specific for recall anti-
gens, and that the distribution of antigen-specific cells within
TCM cell subsets varies for different pathogens.
Next, we compared precursor frequencies of TT-specific
cells in different subsets in donors that had been boosted re-
cently or several years ago (Fig. 6 D). TT-specific cells
were relatively frequent among TEM cells (1:500) in all
donors. Conversely, CXCR5 TCM cells were less frequent
(1:500), especially in donors that had not been boosted
for several years, possibly explaining the failure of previous
studies to detect TT-specific cells in this subset using thy-
midine incorporation (29, 31). Interestingly, the relative
distribution among CXCR3 TCM and CCR4 TCM cells
was highly variable, with some donors having higher num-
bers of CCR4 TCM cells and others containing predomi-
nantly CXCR3 TCM cells. These results indicate that TT-
specific T cells are present in high frequency in TEM cells,
even several years after vaccination, and are distributed in
different subsets of TCM cells.
Discussion
We have shown that the human CD4 TCM cell pool can
be subdivided into subsets of nonpolarized cells and pre-
Th1 and pre-Th2 cells based on chemokine receptor ex-
pression. These subsets have extensively divided in vivo
and contain cells specific for recall antigens and with self-
renewal capacity. Upon TCR-independent proliferation
induced by homeostatic cytokines, TCM cell subsets are
committed for different fates and become Th1, Th2, or re-
main nonpolarized cells, explaining how the quality of the
primary immune response could be maintained by TCM
cells in the absence of antigen.
Th cells expressing CXCR5 comprise CCR7 CD57
follicular Th cells in tonsils (29, 30, 49), and nonpolarized
circulating CXCR5 TCM cells of unknown function and
specificity that might have a recent activation history (31).
Our results show that nonpolarized cells are present in both
CXCR5 and CXCR5 TCM cell subsets and lack CXCR3
and CCR4 expression. Using CFSE dilution we were fur-
ther able to show that CXCR5 TCM cells contained low
numbers of TT-specific cells even several years after vacci-
nation. Moreover, three of four smallpox-vaccinated,
responsive donors contained VV-specific cells at low
frequency in the CXCR5 TCM cell subset. Using quanti-
tative PCR, we found that CXCR5 TCM and CXCR5
TCM cells contained comparable amounts of residual TRECs,
whereas TEM cells had slightly lower levels, suggesting that
TCM cell subsets had divided to a comparable extent (ap-
proximately seven times). However, because naive and
memory cells were identified by CD45 isoform expression
that is not a stable marker (25, 50), the number of divisions
performed by memory cells might be underestimated by
our analysis. Spontaneous BrdU uptake indicated that
CXCR5 TCM cells have an in vivo proliferation rate that
is comparable to that of other memory subsets. The rela-
tive small cell size and the absence of CD69 on BrdU
cells suggest that this proliferation is driven by homeostatic
mechanisms rather than by antigen. Why /TCM cells
have a higher turnover than other memory subsets is cur-
rently unclear. They might be particularly fit because they
combine a relatively high cytokine responsiveness with a
low susceptibility to apoptosis (51). Alternatively, they
might be preferentially located in cytokine-rich microen-
vironments or in proximity to DCs that boost proliferation
in response to IL-7 and IL-15 (21). In any case, these re-
sults show that all CD45RA subsets, including CXCR5
TCM cells, are memory cells that have extensively divided,
slowly turnover in vivo, and contain cells specific for recall
antigens.
Different viruses are known to induce CD8 memory
cells belonging preferentially to different subsets (52, 53).
Here we showed that although pathogen-specific CD4 T
cells are present in both the TCM and TEM cell pools, they
have characteristic distributions in TCM cell subsets, reflect-
ing the Th1/Th2 cell polarization induced by the patho-
gens or vaccinations. Thus, TT-specific cells were detected
in all subsets, consistent with the notion that vaccination
against tetanus induces a mixed Th1/Th2 cell response
(54). Conversely, CMV and VV promote Th1 cell polar-
ization (46, 47), and virus-specific cells were consequently
detected in CXCR3 TCM cells but not in CCR4TCM
cells. In one donor, we were able to show that VV-specific
TEM cells were also CXCR3 (not depicted). Collectively,
these results suggest that immune responses generate het-
erogeneous populations of memory cells that belong to
different subsets and comprise a broad spectrum of differ-
entiation stages. The distribution between CXCR3 and
CCR4 subsets in the TCM and TEM cell pools might be
useful to monitor the quality of the memory response to
different pathogens.
Human memory T cells can be subdivided into CCR7
TCM and CCR7 TEM cells with different effector func-
tions and homing potentials, suggesting a division of labor
between these two subsets (12). However, several recent
reports showed that antigen-experienced CCR7 cells
possess immediate effector functions (9, 32–35). Although
we identified here CCR7 memory cells with IFN-–
and IL-4–producing capacities as CXCR3 TCM and
CCR4 TCM cells, respectively, the following lines of evi-
dence suggest that these cells are not fully differentiated ef-
fectors: (a) they had a higher expansion potential than TEM
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cells and most cells had retained CD27 and CD62L ex-
pression; (b) IFN- production by CXCR3 TCM cells
was low and largely restricted to unconventional CCR7
CD62L cells; (c) although CCR4 TCM cells produced
some IL-4, production of IL-5, which acts on eosinophils
at peripheral sites of allergic inflammation, was limited to
TEM cells; (d) many CXCR3 TCM and CCR4 TCM cells
had retained flexibility to differentiate to Th2 and Th1
cells, respectively, upon antigenic stimulation in the pres-
ence of appropriate polarizing cytokines; and (e) upon
cytokine stimulation, they further differentiated, losing
CCR7 and CD62L and acquiring nonlymphoid homing
potential and high levels of effector functions. Together,
these findings are consistent with the notion that nonlym-
phoid tissue homing potential and effector cytokine–pro-
ducing capacities are progressively acquired upon T cell
differentiation and reside predominantly in the TEM cell
subset of the human CD4 memory cell pool (3). How-
ever, because effector functions and nonlymphoid homing
potentials are acquired in a stochastic manner (55), some
cells have characteristics that are intermediate between
TCM and TEM cells.
We previously proposed that cytokine-driven differenti-
ation of TCM cells might be a mechanism to replenish
short-lived TEM cells in the absence of antigen (21), but
how nonpolarized TCM cells could faithfully maintain po-
larized Th1 or Th2 effector cell populations remained un-
clear. A recent report showed that CD4 T cell priming
upon viral infection generated both short-lived effector
cells and long-lived precursors that lacked effector func-
tions, but spontaneously acquired IFN-–producing ca-
pacity when transferred into antigen-free hosts (26). We
showed here that CXCR3 TCM and CCR4 TCM cells in-
variably differentiated to CCR7 Th1 or Th2 effector cells
in an antigen-independent fashion, whereas CXCR5
TCM cells remained nonpolarized and CCR7. CXCR3
and CCR4 are preferentially induced under type 1
and type 2 priming conditions, respectively (6, 7), and
CXCR3 TCM and CCR4 TCM cells might therefore rep-
resent committed precursors of the Th1 and Th2 cell lin-
eage with the capacity to generate effector cells for
extended periods in the absence of antigen. Unlike cyto-
kines, TCR ligands can still instruct TCM cells to become
Th1 or Th2 cells in the presence of appropriate polarizing
cytokines (13). This differential flexibility might allow the
human immune system to mount qualitatively different re-
sponses in the case of cross-reactive antigens (56), or alter-
natively, to maintain the quality of the primary response
under homeostatic conditions.
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Mouse memory T cell precursors express IL-7Rα, proliferate with homeostatic cytokines and
undergo secondary expansions with antigen. Here we analyzed how the strength of antigenic
stimulation - as determined by DC number, DC maturation state and antigen concentration -
controls IL-7Rα expression and responsiveness to IL-7, IL-15 and antigen in human CD4+ T
cells. We found that T cells primed by different strengths of stimulation expressed IL-7Rα in
different proportions and preferentially on cells that maintained expression of the central
memory marker CCR7. However, while CCR7+IL-7Rhi cells generated at high strength of
stimulation proliferated vigorously in response to IL-7 or IL-15, CCR7+IL-7Rhi cells
generated at low strength of stimulation responded poorly. High cytokine responsiveness was
associated with reduced PTEN expression and enhanced s6-kinase activation, consistent with
efficient receptor coupling to downstream signaling pathways. Interestingly, while
intermediate-stimulated CCR7+IL-7Rhi cells were non-polarized, self-renewed with IL-7 and
expanded with antigen, high-stimulated cells generated Th1 effector cells with cytokines but
showed impaired IL-2 production and survival with antigen. Gene expression analysis
suggested that high-stimulated cells represented pre-Th1 cells with low recall potential and
high metabolic state. Taken together these results demonstrate that IL-7 receptor expression
and coupling are instructed in T cells by the strength of stimulation and suggest that memory
subsets may derive from CCR7+IL-7Rhi precursors that received different strengths of
stimulation.
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Introduction
Naïve T cell priming by antigen-carrying DC can result in different outcomes (1). Suboptimal
T cell activation by immature DC induce an abortive proliferation that is thought to be
important for maintenance of tolerance to tissue antigens (2, 3). Conversely, potent activation
following infection with pathogens leads to effector and memory T cell generation (1),
although persistent antigenic stimulation in chronic viral infections can lead to deletion of
antigen-specific T cells due to clonal exhaustion (4, 5). The cell fate decisions are regulated
by the conditions of T cell priming. Factors such as DC maturation stage, affinity of T cell
receptor (TCR) for antigen, T cell competition for access to DC, and polarizing cytokines, all
contribute to the strength of T cell stimulation and, consequently, determine the functional
output (6). In particular, signal strength determines the “fitness” of primed T cells, i.e. the
capacity to resist death by neglect, to proliferate in response to homeostatic cytokines and to
persist in the absence of antigen in vivo (7).
It is still poorly understood how antigen-primed T cells are selected to survive and
become memory cells. However, it was proposed that IL-7 receptor derived signals play a
non-redundant role in mice since, in the absence of IL-7, memory T cells failed to develop (8-
11). Following acute antigenic stimulation, mouse CD8+ memory cell precursors can be
identified by IL-7 receptor α chain (IL-7Rα) expression at the peak of the proliferative
response (11, 12). These memory precursors show enhanced survival, homeostatic
proliferation and powerful recall response both in vitro and in vivo (11, 12). Nevertheless, IL-
15 might promote memory cell generation in the absence of IL-7 (13-15) and not all IL-7Rhi
expressing cells do necessarily survive and become memory cells (11, 16). Moreover, some
IL-7Rlo cells might persist in a functional inferior state both in mice and in humans (17, 18)
and under conditions of chronic antigenic stimulation IL-7Rhi memory cells do not develop (5,
19, 20). In particular, whether IL-7Rhi cells can possess different fitness or potentials to
become memory cells is currently unclear.
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Human and mouse memory T cells are heterogeneous and can be subdivided into two
broad subsets of central memory (TCM) and effector memory (TEM) cells based on CCR7 and
CD62L expression (21). TCM re-circulate through secondary lymphoid organs and rapidly
proliferate upon antigenic stimulation, but possess only low levels of immediate effector
function. Conversely, TEM can migrate to inflamed non-lymphoid tissues where they exert
immediate effector function, but are susceptible to apoptosis and proliferate poorly in
response to antigen (22-24). The lineage relationship of TCM and TEM remains a matter of
intense investigation. We previously showed that upon antigenic stimulation CCR7+ TCM
differentiate to CCR7− effector cells and that committed precursors in the TCM pool (pre-Th1,
pre-Th2 and pre-CTL) can differentiate spontaneously to TEM-like cells in response to
homeostatic cytokines (23-25). Based on these results we proposed that TCM are
differentiation intermediates (21).
Here we investigated the stimulatory conditions that lead to the generation of human T
cells with the characteristics of memory precursors, namely, high expression of IL-7Rα,
responsiveness to IL-7 and IL-15 and proliferation in response to antigenic re-stimulation.
We found that the expression of IL-7Rα and especially its coupling to the signal transduction
pathway are acquired as a function of increasing strength of stimulation. In contrast, the
capacity to secrete IL-2 and expand in response to TCR stimulation decreases at high strength
of stimulation. These results are consistent with the notion that TCM and TEM are generated at
intermediate strength of stimulation.
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 Results
Modulation of IL-7Rα expression in human CD4+ T cells as a function of signal strength
We assessed IL-7Rα expression dynamics in human naïve CD4+ T cells that were primed by
different strength of stimulation. This was achieved: i) by using low and high concentrations
of TSST to vary the rate of TCR triggering (26); ii) by using low and high numbers of TSST-
loaded DC to vary competition for antigen among T cells (27); and iii) by using immature DC
(iDC) or LPS-matured DC (mDC) that offer different levels of co-stimulation (28) and might
engage T cells in transient and sustained contacts, respectively (29). IL-7Rα was expressed on
virtually all naïve T cells (not shown), but was lost 16 hours after stimulation (i.e. prior to cell
division) selectively on activated T cells that had up-regulated CD69 (Fig. 1a). Notably,
although the different priming conditions resulted in large differences in the fraction of
CD69+ T cell blasts, IL-7Rα was efficiently down-regulated on all activated cells.
On day 7 following stimulation, TSST-responsive cells (TCR-Vβ2+) were analyzed
for CFSE dilution and IL-7Rα expression (Fig. 1b). IL-7Rα was re-expressed in all cases in
cells that had diluted CFSE but the percentage of IL-7Rα+ cells varied widely according to the
priming conditions. In particular, only a small fraction of cells primed by low or high
strengths of stimulation were IL-7Rα+ (27% in culture stimulated by low numbers of
immature DC and 14% in cultures stimulated by high numbers of mature DC pulsed with the
highest TSST dose). In contrast, the percentage of IL-7Rα+ cells was high in cells that
received intermediate strengths of stimulation (67% in cells primed by low numbers of mature
DC pulsed with high TSST dose). Comparable results were obtained when cells were
stimulated for different times with anti-CD3 antibodies alone or in combination with anti-
CD28 antibodies in the absence of DC (not shown).
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Altogether these results show that IL-7Rα is rapidly lost upon T cell priming and that
its re-expression on proliferating cells is optimal at intermediate strengths of stimulation,
reduced in cells that receive low strengths of stimulation and impaired at high signal strength.
IL-7Rα and CCR7 expression define functional subsets of activated T cells
We previously showed that CCR7 expression in primed T cells is regulated by the strength of
stimulation (30). We therefore investigated the expression of CCR7 and IL-7Rα  on
proliferating T cells that received low (102 iDC pulsed with 10 ng/ml TSST), intermediate
(102 mDC pulsed with 10 ng/ml TSST) and high (104 mDC pulsed with 10 ng/ml TSST)
strengths of stimulation (Fig. 2a). As expected, the expression of CCR7 was retained in cells
receiving low strength of stimulation and was progressively lost with increasing signal
strength. At low and high signal strength only few cells expressed IL-7Rα and in both cases
they were mainly CCR7+. Conversely, at intermediate signal strength a large fraction of cells
(58%) expressed IL-7Rα and most cells co-expressed CCR7, although some were CCR7−.
The above results suggest that at an intermediate strength of stimulation different T
cell phenotypes could be generated. We therefore asked whether these T cells have distinct
functional properties. T cells primed at intermediate strength of stimulation were sorted
according to the expression of IL-7Rα and CCR7 and immediately analyzed for cytokine
production. Cells were furthermore either starved overnight or stimulated with IL-7 or TSST-
pulsed DC following re-labeling with CFSE.
Single cell analysis of cytokine production revealed that IFN-γ was secreted by CCR7−
cells whereas IL-2 was more efficiently produced by IL-7Rhi cells (Fig. 2b). Consequently,
most CCR7+IL-7Rhi cells secreted IL-2 only, while CCR7-IL-7Rlo cells produced high
amounts of IFN-γ (Fig. 2b).
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Resistance to overnight starvation was higher in CCR7+ cells (either IL-7Rlo or IL-
7Rhi) as compared to CCR7- cells (Fig. 2c, percentage of viable cells in parentheses).
Interestingly, upon overnight culture a considerable fraction of purified IL-7Rlo and CCR7-
cells spontaneously re-acquired IL-7Rα and CCR7. Consistent with their different survival
and IL-2 producing capacities, subsets purified according to IL-7Rα and CCR7 expression
showed different responses to IL-7 and antigenic stimulation (Fig. 2c). CCR7+IL-7Rhi cells
proliferated vigorously in response to IL-7, IL-15 (not shown) or TSST-pulsed DC. These
responses were decreased in the two single-positive subsets (CCR7+IL-7Rlo and CCR7-IL-
7Rhi) and were impaired in the CCR7-IL-7Rlo subset. Notably, all cells proliferating in
response to IL-7 were CCR7+, independently of whether they were derived from CCR7+ or
CCR7- subsets (Fig. 2c). A similar hierarchy of survival and proliferation in response to
cytokines and antigen was observed in subsets displaying the same phenotype but generated
under low or high strength of stimulation (data not shown).
Altogether the above findings show that primed human CD4+ T cells with a CCR7−IL-
7Rlo phenotype are effector cells that are highly susceptible to apoptosis while CCR7+IL-7Rhi
cells possess characteristics of memory precursors.
Different properties of CCR7+IL-7Rhi cells generated at different strength of stimulation
The results obtained so far suggest that memory precursors are present within the CCR7+IL-
7Rhi subset. However, cells with this phenotype can be generated in all stimulatory conditions,
although at different frequencies. It was therefore important to investigate whether CCR7+IL-
7Rhi T cells generated under different strength of stimulation have the same or different
capacities to respond to cytokines and antigenic stimulation. CFSE-CCR7+IL-7Rhi cells that
proliferated following low, intermediate or high strength of stimulation were sorted 7 days
after priming and re-labeled with CFSE. Low-stimulated CCR7+IL-7Rhi cells showed little or
no proliferation in response to IL-7 or IL-15 and had a high death rate (Fig. 3a and 3b, left
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panels). Intermediate-stimulated CCR7+IL-7Rhi cells proliferated slowly in response to IL-7
and IL-15, survived better and retained expression of CCR7 under these conditions (Fig. 3a
and 3b, central panels). Finally, only high-stimulated CCR7+IL-7Rhi cells proliferated
extensively in response to IL-7 and IL-15, and some lost CCR7 expression, especially in IL-
15-supplemented cultures (Fig. 3 a and 3b, right panels). Furthermore, CCR7- T cells arising
in these cytokine-driven cultures acquired the capacity to produce high amounts of IFN-γ as
compared to cells that in the same culture maintained CCR7 expression (Fig. 3c). Notably,
unlike intermediate-stimulated cells, high-stimulated CCR7+IL-7Rhi cells already displayed a
low level IFN-γ producing capacity after priming (data not shown).
In striking contrast with cytokine-induced proliferation, TCR-induced proliferation
was maximal in cells that received an intermediate strength of stimulation and was severely
reduced in high-stimulated T cells (Fig. 3a). The low expansion potential of high-stimulated
cells was associated with high death rate (Fig. 3b) and impaired IL-2 production, and could be
partially reverted by addition of IL-2, but not by neutralizing antibodies to TNF-α, FasL or
TRAIL (data not shown). CCR7+IL-7Rhi cells that received a low strength of stimulation in
the primary culture also showed suboptimal secondary expansions with antigen.
In summary, high strength of stimulation promotes cytokine responsiveness but
inhibits secondary antigen-driven expansions of primed CCR7+IL-7Rhi T cells. Thus, putative
memory T cell precursors, i.e. cells that combine both cytokine responsiveness and recall
potential, possess a CCR7+IL-7Rhi phenotype and are optimally generated at intermediate
strengths of stimulation.
Signal transduction capacities of the IL-7 receptor on activated human T cells
The different IL-7 responsiveness’ of cells expressing IL-7 receptor α raised the question
whether the IL-7R might have different signaling capacities in cells that had received different
strengths of stimulation. We first used a panel of specific inhibitors to address the signal
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requirements for IL-7 receptor-dependent proliferation of TCR-activated human T cells.
Inhibitors specific for JAK3 (JAK3 Inhibitor 2), PI 3-kinase (LY294002) or TOR
(Rapamycin) blocked IL-7-dependent proliferation (31), while inhibitors specific for src
tyrosine kinases (PP2) and p38 Map kinase (SB202190) did not (not shown). We then
assessed s6 ribosomal protein phosphorylation at Ser 235/236 by immuno-blotting as a read-
out of s6-kinase activity (Fig. 4a), which is controlled by PI-3 kinase and TOR (32-34). High-
stimulated CCR7+IL-7Rhi cells showed increasing phosphorylation of s6 ribosomal protein
following culture with IL-7, IL-15 and anti-CD3 plus anti-CD28 antibodies, respectively.
Strikingly, in intermediate-stimulated cells phosphorylation of s6 ribosomal protein was
efficient following stimulation with anti-CD3/CD28 antibodies and IL-15, but not with IL-7.
Similar results were obtained with antibodies specific for phospho-Ser240/44 (not shown).
We then monitored the expression levels of IL-7 and IL-15 receptor components in
purified CCR7+IL-7Rhi cells generated upon low, intermediate or high strength of stimulation
(Fig. 4b). Surface expression of IL-15Rβ and common γ chain was found to be lower in low-
stimulated cells than in high-stimulated cells, but the differences were small and the receptors
were clearly detectable under all conditions. IL-15Rα  could not be detected in these
conditions (not shown). Interestingly, expression of PTEN, a phosphatase that counteracts PI-
3 kinase activity, was low in high-stimulated cells (Fig. 4b), thus inversely correlating with
IL-7 induced s6-kinase activity and proliferation.
In order to understand if the observed signaling defect in weakly stimulated cells was
specific for PI 3-kinase/PTEN-dependent signaling pathways, we compared phosphorylation
of STAT5 and s6 ribosomal protein at the single cell level by intracellular staining (Fig. 4c).
Consistent with the immuno-blotting results, IL-7 or IL-15 efficiently triggered s6-kinase
activity in high-stimulated cells, but failed to do so in low-stimulated cells and only IL-15
induced efficient s6 ribosomal protein phosphorylation in cells that had received an
intermediate level of stimulation. Interestingly, s6 ribosomal protein phosphorylation occurred
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exclusively in phospho-STAT5hi cells, suggesting a higher activation threshold for activation
of s6-kinase than for JAK. Consistently, STAT5 phosphorylation was readily detectable upon
cytokine stimulation under all conditions, indicating the presence of functional IL-7 and IL-15
receptors. As expected, phosphorylation of s6 ribosomal protein was blocked by Rapamycin
or by a PI-3 kinase inhibitor (not shown).
In summary, a strong T cell stimulation down-regulates PTEN expression and
effectively couples the IL-7R to s6-kinase activation.
Gene expression profile of activated CCR7+IL-7Rhi T cells
In order to further understand how the differential responses to IL-7 and TCR stimulation
could be regulated in primed T cells, we performed global gene expression analysis of FACS-
purified CCR7+IL-7Rhi cells derived from cultures at intermediate and high strength of
stimulation. Microarray gene expression profiles were obtained using Affymetrix GeneChip
Human Genome U133 2.0 Plus arrays, which target over 47,000 transcripts, including 38,500
well-characterized genes.
More than 24,000 genes were expressed in at least one of the experimental conditions.
Differentially expressed genes were selected as those showing a statistically significant
change of at least two-fold in the two replicates. Using this criterion, 408 unique transcripts
(266 increased and 141 decreased) were identified (Supplementary Table 1). To have a broad
picture of the changes in gene expression, we performed a functional annotation analysis of
the 408 genes using the Gene Ontology and the Panther Classification, and Biocarta and Kegg
pathways.  There was no group of functionally related genes over-represented among the 141
down-regulated transcripts. Conversely, functional annotation of the up-regulated genes
showed an over-representation of genes involved in immunity and defense, cell cycle,
apoptosis, regulation of transcription and metabolism such as glykolysis (Table 1 and
supplementary Tables 2 and 3).
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Figure 5 shows the behavior of transcripts that code for gene products with a known
role in immune responses, signaling, cell cycle, regulation of transcription and apoptosis, and
that were up- or down-regulated in CCR7+IL-7Rhi cells from high- as compared to
intermediate-stimulated cultures of at least 4-fold in both experiments. The Figure contains
also some genes that varied less than 4-fold, but that were arbitrarily chosen because of
interesting functions. Among strongly up-regulated genes involved in immune responses there
were several genes involved in Th1 development, including IFN-γ, STAT1, IL-12Rβ2 and
JAK2 (35). The selective expression of IL-12Rβ2 in high-stimulated cells was confirmed by
cell surface staining (not shown). Surprisingly, strongly stimulated cells expressed high levels
of SOCS3, which inhibits JAK activation by several cytokines, including IL-2 and IL-12 (36).
Several genes involved in inhibition of IL-2 production following TCR stimulation, including
CTLA-4 (37), MAP kinase phosphatase 1 (38) and the transcription factors CREM (39) and
SNFT (40) were also expressed at higher levels in high-stimulated cells than in intermediate-
stimulated cells. Conversely, expression of β2 integrin and LAT, which positively regulate
IL-2 production upon TCR stimulation (41-43), were reduced. Moreover, high-stimulated
cells expressed significantly higher levels of crucial cell cycle regulators including CDK2,
CDK6, CDC6 and cyclin E2 as well as the Ki67 antigen (the latter also at the protein level,
not shown). They also expressed moderately higher levels of several pro-apoptotic molecules,
including TRAIL, while an apoptotic inhibitory molecule was reduced.
Overall these results suggest that high-stimulated T cells can sustain a high metabolic
rate and have a low threshold to cycle with mitogens. Moreover, the data are consistent with
Th1 commitment of high-stimulated cells and provide a plausible explanation for their
reduced IL-2 production and survival following antigenic re-stimulation.
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Discussion
The signals that regulate the generation of memory T cells from antigen-activated precursors
are a field of intense research. We showed here that the strength of stimulation of human
CD4+ naive T cells upon priming regulates the generation of CCR7+IL-7Rhi cells, their
capacity to proliferate and differentiate with IL-7 and their expansion potential following
antigenic re-stimulation, i. e. their potential to become long-lived memory cells. In particular
we found that CCR7+IL-7Rhi cells differ in their capacity to signal via the IL-7 receptor and in
the expression of genes that regulate survival, proliferation and differentiation.
IL-7 is a key cytokine that regulates naïve and memory T cell survival and
homeostatic proliferation as well as memory cell generation from activated precursors (8-10,
44-47). The expression of its receptor is known to be modulated upon T cell activation and is
down-regulated by IL-2 (48), IL-7 (49) and chronic antigenic stimulation as it occurs in
persistent virus infections (5, 17, 19, 20). We showed here that the early loss of IL-7Rα on
activated T cells is largely independent of the priming conditions, while the later appearance
of dividing IL-7Rα+ cells is regulated by signal strength and is optimal at intermediate
strength of stimulation. We mimicked tolerogenic priming that occurs under steady state
conditions and results in abortive T cell proliferation (2) by weak stimulation with low
numbers of immature DC and were surprised to find that a considerable fraction of
proliferating cells re-acquired IL-7Rα under this condition. However, these IL-7Rhi cells
survived poorly and did not proliferate with IL-7 or IL-15 and were thus unfit to become
memory cells (7). These findings are consistent with the notion that IL-7Rα expression is not
sufficient per se to predict the memory potential of activated T cells (13, 16).
Activated CD8+ mouse T cells that perform immediate effector functions or that
become long-lived memory cells and mediate protective immunity can be identified by
expression of IL-7Rα and lymph node homing receptors, such as CCR7 and CD62L (11, 12,
50, 51). We found that in human CD4+ T cells IL-7Rα and CCR7 expression can be used to
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identify subsets with characteristics of memory or effector cells. Remarkably however, cells
with a putative memory precursor phenotype, i.e. CCR7+IL-7Rhi had strikingly different
responses to IL-7 and TCR ligands that were dependent on the strength of stimulation
received during priming. In particular, CCR7+IL-7Rhi cells generated upon intermediate signal
strength were non-polarized, proliferated slowly with IL-7 but expanded efficiently upon TCR
re-stimulation and therefore possessed characteristics of circulating non-polarized TCM cells
(24). Conversely, high-stimulated CCR7+IL-7Rhi cells showed poor capacity to proliferate
upon TCR re-engagement, but proliferated efficiently with homeostatic cytokines and
differentiated spontaneously to Th1 effector cells, and therefore have characteristics of pre-
Th1 central memory cells that have been described both in the mouse and in human blood (24,
52, 53). Interestingly, efficient Th1 lineage commitment of high-stimulated cells required
high concentrations of TSST, but was not prevented by neutralizing anti-IL-12 antibodies
(data not shown).
CCR7-IL-7Rhi can be generated upon antigenic stimulation in low numbers. However,
these cells had a high death rate and spontaneously re-acquired CCR7 upon withdrawal of
TCR agonists. This phenotypic reversion has been originally described for in vivo primed
TCR-transgenic CD8+ mouse T cells following adoptive transfer (51), although it was later
shown not to occur at physiological precursor frequency (54). TCR-Vβ2+ cells also have a
high frequency among human T cells and we also detected a reduced phenotypic reversion
and enhanced survival of CCR7-IL-7Rhi cells when the competition for antigen was reduced.
It is therefore possible that CCR7-IL-7Rhi generated upon infections or vaccinations in vivo
contribute to a higher extent to the TEM pool than suggested by our results.
The observed striking differences in IL-7 responsiveness of CCR7+IL-7Rhi T cells
derived from low, intermediate and high-stimulated cultures are unlikely to be caused by
cytokine receptor expression levels. Indeed, common γ chain expression and IL-7-induced
STAT5 phosphorylation were comparable in cells receiving low or high stimulation. These
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results suggest that all IL-7Rhi cells possess a functional IL-7R, but that the cellular context in
which IL-7 receptor-derived signals act is different. IL-7 and other common γ cytokines are
known to maintain the metabolic rate of T cells and to alter the expression of critical survival
factors and cell cycle regulators (31, 32, 55). Gene expression analysis suggested that the
enhanced IL-7 responsiveness and fitness of strongly stimulated cells reflected a higher
metabolic rate and partially pre-build cell cycle machinery (56). Moreover, we found that
protein expression levels of the critical inhibitory phosphatase PTEN (57) were reduced in
high-stimulated cells. Consistent with more efficient signaling via PTEN-regulated pathways,
we found that s6 ribosomal protein phosphorylation, which is important for translation of
ribosomal components and cell cycle regulators, required strong TCR stimulation. Thus, the
strength of stimulation can license the IL-7 receptor to signal for proliferation by altering a
key component of the signal transduction machinery that couples membrane-proximal
signalling to cell cycle progression. Interestingly, high PTEN levels also correlated with low
IL-2 responsiveness of CD25+ T regulatory cells in the mouse (58), suggesting that PTEN
expression levels in T cells might be a conserved mechanism regulating responsiveness to
common γ cytokines. Consistently, low-stimulated cells failed to phosphorylate s6 ribosomal
protein in response to either IL-7 or IL-15. Surprisingly however, IL-15, but not IL-7 induced
s6 kinase activity in T cells primed with an intermediate level of stimulation (Fig. 4a). A
possible explanation for this finding is that IL-7, unlike other common γ cytokines, down-
regulates its own receptor (49) and therefore inhibits its own signaling.
Despite their high cytokine responsiveness high-stimulated T cells failed to undergo
efficient secondary expansion following antigenic re-stimulation. This defect was associated
with cell death and reduced IL-2 production in response to stimulation with TSST, but not
with phorbol esters and ionomycin (data not shown), suggesting an early signaling defect.
Gene expression analysis revealed that several critical molecules affecting TCR-dependent
IL-2 production were altered, including LFA-1, CTLA-4 and LAT. Moreover, the
69
unexpectedly high SOCS3 expression in high-stimulated cells did not lead to reduced STAT5
phosphorylation (Fig. 4c), but might inhibit IL-2 production following TCR stimulation (59).
Exogenous IL-2, but not antibodies neutralizing death-inducing cytokines, enhanced
accumulation of TCR re-stimulated cells (not shown), suggesting that death receptor-induced
apoptosis was not limiting cellular expansion under these conditions (60).
In summary we have shown that the strength of stimulation of CD4+ T cells
determines the memory potential and lineage commitment of activated T cells that is not
predictable by phenotypic markers. Our work might be helpful to identify conditions for the in
vitro generation of human antigen-specific T cells with desired properties to improve
vaccination and adoptive immunotherapy.
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Materials and Methods
Cell culture. PBMC were isolated from buffy-coated blood from healthy donors. Monocytes
were purified by positive selection with anti-CD14 beads (Miltenyi). For DC differentiation,
CD14+ cells were cultured for 4 days in complete medium (RPMI 1640 supplemented, 2 mM
glutamine, 1% non-essential amino acids, 1% sodium pyruvate, 50 µg/ml kanamycin, 50U/ml
Penicillin and 50 µg/ml streptomycin, Gibco) containing 10% FCS (Hyclone), 50 ng/ml GM-
CSF (Novartis) and 1000 Units (U)/ml IL-4. The DC obtained were stimulated for 24 hours
with 100ng/ml LPS (Salmonella abortus equi, Sigma) and pulsed for 30 minutes with TSST.
Total CD4+ T cells were isolated from the CD14- fraction by negative selection with a CD4+ T
cell isolation kit on an Automacs (Miltenyi). CD4+ T cells were stained with anti-CCR7 mAb
(R&D systems) followed by a biotin-labeled anti-γ2a antibody and labeled streptavidin, FITC-
labeled anti-CD45RA and PC5-labeled anti-CD8, anti-CD16 (Beckmann Coulter) and anti-
CD19 (Becton Dickinson) and naïve CD4+ T cells (CD45RA+CCR7+) were purified by cell
sorting to >99%. Labeling of naïve or activated T cells with CFSE was performed as
described previously (25). 104 CFSE-labeled naïve T cells were co-cultured with TSST-pulsed
DC in round bottom wells, and stained after 16 hours with CD69-APC and IL-7Rα−PE. After
7 days CFSElo cells were purified on a FACSAria (Becton Dickinson) according to CCR7 and
IL-7Rα expression (IL-7Rα mAbs, Beckmann coulter and R&D system), cells were relabeled
with CFSE and 104 cells cultured in the absence or presence of recombinant cytokines IL-7,
IL-15 (25ng/ml, R&D systems) or autologous TSST-pulsed DC. Cell viability was assessed
by exclusion of propidium iodide at 1 µg/ml. Protein kinase inhibitors were used at optimal
concentrations after a pre-incubation for 30 minutes at 37C as described (25): the src tyrosine
kinase inhibitor PP2 at 1µM (Alexis), the JAK3 2 Inhibitor at 25 ng/ml (Alexis), the PI3-
kinase inhibitor LY294002 at 10µM (Cell Signaling), Rapamycin at 100nM (Cell Signaling)
and the p38 inhibitor SB202190 at 10 µM (Alexis).
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Intracellular staining. Cytokine producing capacity of FACS-purified subsets was assessed
after stimulation of purified cell populations at 104/ 1 0 0 µ l for 24h with 50 nM
Phorboldibutyrate (PdBu, Sigma) and 0.5 µg/ml Ionomycin (Sigma) or in wells coated with
anti-CD3 (clone TR66) and anti-CD28 antibodies (Pharmingen BD, 2 µg/ml each).
Intracellular IL-2 and IFN-γ was detected after stimulating cells for 6 hours in the presence of
10 µg/ml Brefeldin A (Sigma) for the last 2 hours and after fixation with paraformaldehyde
4% and permeabilization with saponin (Sigma). After saturation of non-specific binding sites
with 10% FCS, cells were incubated with labeled antibodies to IFN-γ and IL-2 (Pharmingen),
washed and analyzed by flow cytometry on a FACSCalibur with the CellQuest software
(Becton Dickinson). For intracellular staining of phospho-proteins or PTEN (Cellsignalling),
purified cells were cultured in the absence or presence of recombinant cytokines or with
immobilized anti-CD3 plus anti-CD28, and cells were treated following the manufactor’s
instructions. Briefly, cells were washed, fixed for 10 minutes at 37C with 1%
paraformaldehyde followed by incubation in Metahnol on ice for 30 minutes, non-specific
sites blocked with 0.5% BSA for 30 minutes at room temperature and cells were stained for
intracellular phospho-STAT5 with a labeled mouse antibody (Beckton Dickinson) and
phospho-s6 ribosomal protein or PTEN was detected with a specific rabbit antibody (Cell
Signaling) followed by incubation with a labeled multiple-adsorbed anti-rabbit antibody
(Jackson lab).
Immunoblotting. Cell lysates (Tris-Cl 50mM pH 7.4, NP-40 0.5%, 0.15M NaCl, 2 mM
EDTA, 10 mM NaF, 10 mM P207, 0.5 mM Na3VO4, 100 µg/ml PMSF, 1mg/ml Aprotinin
and Leupeptin) were cleared by centrifugation, boiled in sample buffer and resolved on a 10%
SDS-PAGE. Proteins were transferred on a nitrocellulose membrane (Amersham).
Incubations with the primary anti-phospho-s6 ribosomal protein antibodies (Cellsignalling)
and secondary, horseradish peroxidase-conjugated antibodies were performed in blocking
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buffer (5% dry non-fat milk in Tris buffered saline pH 7.4 containing 0.05% Tween 20
(TBST). Blots were developed with an ECL kit (Amersham).
Microarray and data analysis. FACS-purified CFSEloCCR7+IL-7Rhi cells (>106) generated
upon stimulation with 102 or 104 TSST-loaded mature DC were obtained from two different
donors and analyzed separately. RNA was extracted with the TRIzol method (Invitrogen).
RNA concentration was determined using a Nanodrop spectrophotometer (Witec). RNA
quality was verified using the 2100 BioAnalyzer (Agilent Technologies). Total RNA (2µg)
was labeled and hybridized with the GeneChip Expression 3’ Amplification One-Cycle target
labeling kit on Affymetrix GeneChip Human Genome U133 2.0 Plus arrays (Affymetrix)
according to the manufacturer’s protocol. Washes and scanning were done according to the
Affymetrix protocols with a Fluidics Station 400 and a GeneChip Scanner 3000 (Affymetrix).
Data analysis was carried out using the GeneChip Operating System (GCOS) 1.4
(Affymetrix). For normalization, the output of each experiment was multiplied by a scaling
factor to bring its average to a target intensity of 200. The standard GCOS Detection
algorithm was used to determine the call Present (P), Absent (A) or Marginal (M) for each
probe set in each experimental condition. The standard GCOS Change and Signal Log Ratio
(SLR) algorithms were used to identify differentially expressed genes comparing the
CCR7+IL-7Rhi cells stimulated with 104 TSST-loaded mature DC against the CCR7+IL-7Rhi
cells stimulated with 102 TSST-loaded mature DC as baselines. Based upon the p-values, the
Affymetrix default settings define Increase (I) Change, Marginal Increase (MI) Change, No
Change (NC), Marginal Decrease (MD) Change and Decrease (D) Change calls. The outputs
of the SLR algorithm are values in log scale of base 2, thus SLR values of 1 and -1 indicate a
2-fold increase or a 2-fold decrease, respectively.
Genes showing an Increase Change call plus SLR ≥ 1 in both replicates or showing a Decrease
Change call plus SLR ≤ -1 in both replicates were considered as differentially expressed between
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the CCR7+IL-7Rhi cells stimulated with 104 TSST-loaded mature DC and the CCR7+IL-7Rhi cells
stimulated with 102 TSST-loaded mature DC. Probe sets defined as absent in all the experiment
conditions were discarded; probe sets were also discarded when having an Increase Change call
plus SLR ≥ 1 but with a call Absent in the CCR7+IL-7Rhi cells stimulated with 104 TSST-loaded
mature DC, or when having a Decrease Change call plus SLR ≤ -1 but with a call Absent in the
CCR7+IL-7Rhi cells stimulated with 102 TSST-loaded mature DC. Functional characterization
was performed to identify groups of functionally similar genes over-represented among the
differentially expressed genes in comparison with the whole population of human genes.  The
Database for Annotation Visualization and Integrated Discovery 2.0 tool (National Institute of
Allergy and Infectious Disease, Frederick, MD, USA) was used for identification of Gene
Ontology classes, Kegg and Biocarta pathways (61). The Panther Gene Expression Data
Analysis tool (Applied Biosystems) was used for Panther ontology classes and pathways (62). A
p-value lower than 0.01 was used as a cut-off to identify statistically significant over-represented
functional classes. Raw microarrays expression data will be made publicly available through
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/).
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Figure legends
Figure 1. Expression of IL-7Rα on primed T cells is regulated by the strength of antigenic
stimulation. Purified human CD4+ naïve T cells were stimulated as indicated with 102 or 104
immature (iDC) or LPS-matured monocyte-derived DCs (mDC) loaded with 0.1 or 10 ng/ml
TSST. a) After 16 hours T cells were stained for CD69 and IL-7Rα expression and analyzed by
flow cytometry. Grey dots represent small cells and black dots show blasts. Upper numbers
indicates the fraction of activated CD69+ blasts, and lower numbers in parenthesis the percentage
among CD69+ blasts that have lost IL-7Rα expression. Results are representative of three
separate experiments. b) After 7 days IL-7Rα expression and CFSE dilution were analyzed by
gating on TCRVβ2+ cells. Numbers indicate the fractions of CFSElo cells that express IL-7Rα.
Results are representative of four separate experiments.
Figure 2. CCR7 and IL-7Rα expression identify subsets of primed CD4+ T cells. a)
Expression of CCR7 and IL-7Rα on CFSElo T cells on day 7 following priming with low (102
iDC, 10ng/ml TSST), intermediate (102 mDC, 10ng/ml TSST) or high (104 mDC, 10ng/ml
TSST) strength of stimulation. b) Secretion of IL-2 and IFN-γ by cells primed at intermediate
strength of stimulation and sorted according to IL-7Rα and CCR7 expression following re-
stimulation with PdBu and ionomycin for 6 hours. c) Phenotypes and proliferation of
intermediate-stimulated cells sorted for CCR7 and IL-7Rα expression immediately after
sorting, after overnight culture in medium alone, or after 7 days culture in the presence of
25ng/ml IL-7 or TSST-pulsed mDCs (DC-T cell ratio, 1:5). Numbers in parenthesis indicate
cell viability following overnight rest. Results are representative of four separate experiments.
Figure 3. Expansion of CCR7+IL-7Rhi cells in response to IL-7 or antigenic stimulation
has different requirements. Purified naïve CD4+ CFSE-labelled T cells were stimulated with
low, intermediate, or high strength of stimulation (as specified in Figure 2) and
CFSEloCCR7+IL-7Rhi subsets purified by cell sorting. Cells were re-labelled with CFSE and
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cultured with IL-7, IL-15 or TSST-pulsed DCs for 7 days. a) CFSE dilution and CCR7
modulation of viable TCRVβ2+ cells. Numbers indicate -fold expansion b) Cell viability
assessed by PI staining. Numbers indicate percentages of PI+ cells c) After culture with IL-7
for 7 days T cells were stimulated for 6 hours with phorbole ester and ionomycin and IFN-γ 
versus CFSE dilution was analyzed according to CCR7 expression. Numbers indicate
percentage of IFN-γ secreting cells. Results are representative of three separate experiments.
Figure 4. A strong TCR stimulation licenses the IL-7R to trigger s6 kinase activity.
a) Naive T cells were primed with intermediate (102 mDCs, 10 ng/ml TSST) or high (104
mDCs, 10 ng/ml TSST) strength of stimulation. After 7 days CFSEloCCR7+IL-7Rhi cells were
purified and rested or stimulated with IL-7, IL-15 or anti-CD3/CD28 antibodies.
Phosphorylation of s6 ribosomal protein at Ser 230/5 was analysed by immunoblotting. One
experiment out of three. b) Purified CFSEloCCR7+IL-7Rhi cells from low-, intermediate- or
high-stimulated cultures were purified and analyzed for cytokine receptor or PTEN expression
by surface and intracellular staining, respectively. Jurkat cells stained negative for PTEN (not
shown). Numbers indicate mean fluorescence intensities. c) Cells primed under the indicated
conditions were cultured in the absence or presence of IL-7 or IL-15 and phosphorylation of
STAT5 and s6 ribosomal protein were assessed by intracellular staining. Results are
representative of five separate experiments.
Figure 5. Gene expression analysis of CFSEloCCR7+IL-7Rhi cells. The relative changes of
genes with known roles in immune response, signalling, cell cycle, transcription and apoptosis
that were strongly up- or downregulated (>4 times) in high-stimulated cells are shown. Some
genes that were only moderately altered (2-4 fold), but codified for interesting gene products
are also shown. Genes of particular interest are in bold. Numbers indicate the fold-increase
when exceeding 30-fold or the fold-reduction when exceeding 12-fold.
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Table 1. Functional annotation according to Panther classification of 266 genes up-regulated
with at least a two-fold change in CCR7+IL-7Rhi cells stimulated with 104 TSST-loaded
mature DCs (high strength of stimulation) when compared with CCR7+IL-7Rhi cells
stimulated with 102 TSST-loaded mature DCs (intermediate strength of stimulation).
Panther Ontology Panther Ontology Term
Number of
genes P-value
Biological Process Interferon-mediated immunity 11 2.70E-08
Glycolysis 9 1.75E-07
Cell cycle 31 4.65E-07
Immunity and defense 37 1.79E-06
Chromosome segregation 9 7.16E-04
Cell cycle control 15 3.73E-03
Stress response 10 6.72E-03
Molecular Function Kinase 19 4.06E-03
File: Lozza et al. supl.Table 1.xls
Supplementary Table 1. List of 408 differentially expressed genes with at least a two-fold
change in CCR7+IL-7Rhi cells stimulated with 104 TSST-loaded mature DCs when compared
with CCR7+IL-7Rhi cells stimulated with 102 TSST-loaded mature DCs.
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Gene Ontology
Classification Gene Ontology Term
Number of
genes P-value
Biologic Process Cell Proliferation 52 7.40E-17
Cell Cycle 41 7.49E-15
Mitotic Cell Cycle 19 3.65E-11
Nuclear Division 16 1.61E-09
Cellular Physiological Process 93 3.19E-09
M Phase 16 3.60E-09
Regulation Of Cell Cycle 23 4.09E-09
Mitosis 13 5.87E-08
M Phase Of Mitotic Cell Cycle 13 8.20E-08
Cell Growth And/Or Maintenance 81 9.44E-08
Alcohol Metabolism 16 4.85E-07
Response To Stress 30 5.87E-07
Regulation Of Cellular Process 28 1.59E-06
Cell Cycle Checkpoint 7 4.04E-06
Glycolysis 8 9.18E-06
Physiological Process 173 1.90E-05
Regulation Of Cell Proliferation 14 2.14E-05
Glucose Catabolism 8 2.48E-05
Gluconeogenesis 6 3.15E-05
Macromolecule Metabolism 66 5.38E-05
Hexose Catabolism 8 5.80E-05
Alcohol Catabolism 8 6.27E-05
Monosaccharide Catabolism 8 6.27E-05
Alcohol Biosynthesis 6 7.63E-05
Hexose Biosynthesis 6 7.63E-05
Monosaccharide Biosynthesis 6 7.63E-05
Response To DNA Damage Stimulus 12 1.31E-04
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Sterol Metabolism 7 1.40E-04
Chromosome Segregation 5 1.79E-04
Response To Endogenous Stimulus 12 2.03E-04
Glucose Metabolism 8 2.30E-04
Carbohydrate Catabolism 8 2.59E-04
Sterol Biosynthesis 5 2.87E-04
Cellular Process 110 2.91E-04
Hexose Metabolism 9 3.07E-04
Monosaccharide Metabolism 9 3.53E-04
Metabolism 117 4.46E-04
DNA Repair 10 7.48E-04
Cholesterol Metabolism 6 8.25E-04
Carbohydrate Biosynthesis 7 8.98E-04
Apoptosis 15 9.55E-04
Programmed Cell Death 15 1.02E-03
Negative Regulation Of Transcription From
Pol II Promoter 6 1.03E-03
Chromosome Condensation 4 1.03E-03
Regulation Of Biological Process 54 1.12E-03
Negative Regulation Of Cell Proliferation 8 1.24E-03
Transcription From Pol II Promoter 15 1.26E-03
Steroid Metabolism 8 1.41E-03
Cell Death 15 1.70E-03
Death 15 1.88E-03
Meiosis 5 1.89E-03
G2/M Transition Of Mitotic Cell Cycle 5 2.06E-03
Cholesterol Biosynthesis 4 2.54E-03
Regulation Of Transcription From Pol II
Promoter 10 2.82E-03
Meiosis I 4 2.88E-03
87
Meiotic Prophase I 4 2.88E-03
DNA Recombination 6 3.61E-03
Mitotic Chromosome Condensation 3 3.85E-03
Mitotic Prophase 3 3.85E-03
Negative Regulation Of Transcription, DNA -
Dependent 6 3.99E-03
G1/S Transition Of Mitotic Cell Cycle 5 4.30E-03
Negative Regulation Of Nucleobase,
Nucleoside, Nucleotide And Nucleic Acid
Metabolism 7 4.88E-03
Protein Amino Acid Phosphorylation 17 5.72E-03
Biosynthesis 25 5.98E-03
Lipid Biosynthesis 8 5.99E-03
Steroid Biosynthesis 5 8.20E-03
DNA Metabolism 16 8.49E-03
Regulation Of Mitosis 4 9.15E-03
Macromolecule Biosynthesis 19 9.37E-03
Response To Stimulus 54 9.89E-03
Cellular Component Intracellular 114 1.08E-06
Cytoplasm 70 4.16E-06
Spindle 6 2.14E-04
Nucleus 60 4.72E-04
Spindle Pole 5 6.61E-04
Endoplasmic Reticulum 14 8.28E-04
Condensed Chromosome 4 1.25E-03
Chromosome 10 1.56E-03
Microtubule Cytoskeleton 9 2.03E-03
Microtubule Organizing Center 4 7.41E-03
Molecular Function ATP Binding 39 2.64E-09
Purine Nucleotide Binding 45 3.07E-09
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Adenyl Nucleotide Binding 39 3.78E-09
Nucleotide Binding 45 5.97E-09
Transcription Factor Binding 12 8.70E-05
Catalytic Activity 85 1.29E-04
Transferase Activity 36 1.47E-04
Transferase Activity, Transferring
Phosphorus-Containing Groups 25 1.84E-04
Transcription Cofactor Activity 11 1.96E-04
Protein Serine/Threonine Kinase Activity 13 1.68E-03
Transcription Corepressor Activity 6 1.94E-03
Magnesium Ion Binding 8 2.55E-03
Phosphotransferase Activity, Alcohol Group
As Acceptor 18 3.23E-03
Map Kinase Phosphatase Activity 3 4.39E-03
Specific RNA Polymerase II Transcription
Factor Activity 4 4.51E-03
Protein Serine/Threonine Phosphatase
Activity 5 5.35E-03
Kinase Activity 20 5.68E-03
Protein Kinase Ck2 Activity 8 6.52E-03
Camp-Dependent Protein Kinase Activity 8 7.17E-03
Heat Shock Protein Activity 4 8.88E-03
Supplementary Table 2. Functional annotation according to the Gene Ontology of 266 genes
up-regulated with at least a two-fold change in CCR7+IL-7Rhi cells stimulated with 104 TSST-
loaded mature DCs when compared with CCR7+IL-7Rhi cells stimulated with 102 TSST-
loaded mature DCs.
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Database Pathways
Genes
Observed P-value
Biocarta Epo signaling pathway 5 3.03E-03
Tpo signaling pathway 5 3.74E-03
Glycolysis pathway 4 4.30E-03
IL12 and Stat4 Dependent Signaling Pathway
in Th1 Development 5 4.55E-03
Inhibition of Cellular Proliferation by Gleevec 5 4.55E-03
NO2-dependent IL 12 Pathway in NK cells 4 9.50E-03
Kegg Glycolysis / gluconeogenesis 8 2.05E-04
Cell cycle 8 4.01E-03
Panther Glycolysis 7 2.33E-06
Apoptosis signaling pathway 10 2.44E-04
Supplementary Table 3. Over-represented Biocarta, Kegg and Panther pathways among 266
genes up-regulated with at least a two-fold change in CCR7+IL-7Rhi cells stimulated with 104
TSST-loaded mature DCs when compared with CCR7+IL-7Rhi cells stimulated with 102
TSST-loaded mature DCs.
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Abstract
Two types of regulatory T cells have been described: anergic CD25
+
Foxp3
+ 
“natural” Tregs
and IL-10 secreting “adaptive” Tr1 cells with unknown phenotype. Here we show that CCR6
expression on antigen-experienced T cells requires a tolerogenic cytokine environment, but is
not necessarily associated with Foxp3 induction. Circulating human CCR6
+
CD25
-
memory T
cells are largely Foxp3
-
, they secrete IL-10 in response to self-antigens and inhibit
autoreactive T cell proliferation in an IL-10-dependent manner. Cells specific for self-
antigens in healthy donors are contained exclusively within the CCR6
+ 
population, while
cells with the same specificities are also detected among the CCR6
-
cells in patients affected
by an autoimmune pathology. Unlike naturally occurring CD25
+ 
Tregs, CCR6
+ 
memory T
cells secrete IL-2 and proliferate in response to recall antigens. Single cell analyses of self-
specific CCR6
+
T cells showed that they proliferate and produce IL-10, but not IL-2, in
response to cross-reactive self-antigens. We propose that CCR6 expression marks memory
cells that act as Tr1-like cells when encountering innocuous antigens but behave as memory
cells in response to recall antigens.
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Introduction
It is now widely accepted that regulatory T cells exist and that they are important for
the control of autoimmune diseases and for limiting immune responses
1
. “Natural” Tregs can be identified by CD25 surface expression in both mice 
2, 3 
and humans
4-9
. They mature in the thymus 
10-12 
or in the periphery following tolerogenic priming 
13-17
, are
anergic in vitro but not in vivo 
18, 19 
and lack IL-2 producing capacity 
1, 2, 4-6 
. Their
maintenance and function relies on IL-2 that is produced probably by activated T cells 
20-24
.
They inhibit T cell priming in vitro by a not fully understood cell contact-dependent
mechanism 
4-6, 25
, while in vivo tolerogenic cytokines also seem to play a role 
26-28
. It is
believed that these cells represent an independent T cell lineage that is under the control of
the transcription factor Foxp3 
29-32
. Their T cell receptor repertoire is biased towards
autoreactivity 
7, 12, 33, 34 
and they have been shown to prevent autoimmune diseases in several
different models 
35, 36
. On the other hand, ‘adaptive” or Tr1 cells have also been shown to be
important for control of autoimmune diseases 
37 
and they are believed not to belong to the
natural Treg lineage 
35, 36, 38-40
. They are characterized by their capacity to produce IL-10 and
to inhibit immune responses in an IL-10-dependent manner 
37, 40, 41 
. These cells can be
generated in vitro by tolerogenic priming with immature DC, IL-10 or immune-suppressive
drugs 
37, 42, 43 
, but until now no surface markers which allow the identification of Tr1 cells
have been described and it is currently not clear if they are stably maintained. CCR6 is a
chemokine receptor expressed on B cells, a fraction of memory T cells 
44, 45 
and immature DC
46-49 
. The ligand of CCR6, CCL20 is widely expressed constitutively in lymphoid and non-
lymphoid tissues and up-regulated upon inflammation, but the CCR6-CCL20 axis appears to
be particular important for migration of immune cells to the gut and the skin 
49, 50
. Studies on
CCR6 deficient mice indicated a non-redundant role for CCR6 in gut lymphoid tissue
homeostasis 
50,
51
. Furthermore, CCR6 deficient mice have altered CD4
+ 
T cell responses, including reduced
contact hypersensitivity and enhanced delayed type hypersensitivity responses
51-53 
.
CCL20/CCR6 are further involved in several autoimmune diseases including psoriasis 
54
,
inflammatory bowel disease 
55, 56 
and rheumatoid arthritis 
57, 58
.
Here we show that CCR6 induction and maintenance on human peripheral blood T cells
requires tolerogenic priming. CCR6
+ 
T cells represent a broad subset of human Foxp3
-
CD25
-
antigen-experienced T cells that secrete IL-10 in response to self-antigens and inhibit
autoreactivity in an IL-10-dependent manner. This Tr1-like suppressive capacity is however
110
context-dependent, since single-cell analyses revealed that autoreactive CCR6+T cells also
secrete IL-2 and proliferate in response to recall antigens.
Materials and Methods
Cell culture. Peripheral blood mononuclear cells (PBMC) were isolated from buffy-coated
blood from healthy or autoimmune patients. CD4
+ 
T cells were isolated by negative selection
with magnetic beads using a CD4
+
T cell isolation kit and Automacs (Miltenyi). T cell
subpopulations were purified by cell sorting based on expression of CD45RA, CD25 and
CCR6 at a purity of >95%. Cells were cultured in complete medium (RPMI 1640
supplemented, 2 mM glutamine, 1% non-essential amino acids, 1% sodium pyruvate, 50
µg/ml kanamycin, 50U/ml penicillin and 50 µg/ml streptomycin, Gibco) containing 5%
pooled human serum or autologous plasma. Labelling of T cells with CFSE was performed as
described previously. Monocytes were purified by positive selection with anti-CD14 beads
(Miltenyi). CD14+ cells were directly used for antigen presentation or were cultured with IL-
4 and GM-CSF for 5-7 days, as described previously. Mature monocyte-derived DCs were
obtained by stimulating cells at day 5-6 for 24h with LPS (used 100ng/ml, Invivogen, ultra-
pure LPS). CFSE labelled T cells were co-cultured with autologous DCs in the presence of
TSST (100ng/ml), in 96 round-bottom wells. Circulating myeloid DC were isolated by cell
sorting following enrichment for CD11c
+ 
cells with magnetic beads. 2x10
4 
CFSE-labelled
CD4+T cells were cultured with autologous or allogenic mDCs in 96-round bottom wells at a
5:1 ratio or with autologous monocytes at a 1:1 ratio. Recombinant cytokines were used at
the concentrations of 25ng/ml (TGF-β purchased from R&D, IL-2, IL-10, IL-4, IL-12,
purchased from Pharmingen BD), while neutralizing antibodies to IL-10 and IL-2 or MHC
class II (Pharmingen BD) were used at the concentration of 10µg/ml. Recombinant antigens
were used at
the following concentrations: MelanA 0.1 and 1 µg/ml (Prospec), tetanus toxoid (kindly
provided by Chiron, Siena) 1 µg/ml.
ELISA and intracellular staining. Cytokine producing capacity of T cell subsets purified by
cell-sorting was assessed after stimulation of cells at the density of 25x10
3
/100µl for 24h in
wells coated with 2 µg/ml of anti-CD3 (clone TR66) and anti-CD28 antibodies (Pharmingen
BD). Cell culture supernatants were then assessed by ELISA for presence of cytokines
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following a standard protocol. Analyses was performed with the Softmax program.
Intracellular cytokines were detected after stimulating cells in the presence of 10 µg/ml
Brefeldin A (Sigma) for the last 2 hours of culture and after fixation with 4% formaldehyde
and permeabilization with saponin. After saturation of non-specific binding sites with 10%
FCS, cells were incubated with FITC-labelled antibody to TNF-α and PE-labeled antibody to
IL-2, washed and analysed by flow cytometry on a FACSCalibur with the CellQuest software
(Becton Dickinson). Intracellular Foxp3 was detected with a staining kit by following the
manufacturer’s instructions (e-bioscience).
Recall responses and T cell clones. Antigen specificity of cell-sorted memory CD4+T cell
subsets was assessed by co-culturing purified CFSE labeled T cell subsets with irradiated
autologous monocytes, at a 1:1 ratio, in the presence or absence of recombinant antigens, in
96 U-bottom wells. On days 5 and 7, cells were stained for CD14 and CD25, and CFSE
dilution of CD14
-
cells was assessed and analysed for CD25 expression. In some experiments,
the presence of antigen-specific cells was confirmed by restimulating cells with autologous
monocytes with or without antigen followed by assessment of cytokine production of
proliferating T cells by intracellular staining, as described above. Isolation of autoreactive T
cells was performed by stimulating CFSE labeled T cells with autologous mDCs and by
sorting the population of divided cells at day 7. Single cell cloning of the autoreactive
population was performed by limiting dilution by plating cells in 96 U-bottom wells at a
concentration of 0.5 cells/well in the presence of 1x10
6
/ml irradiated allogeneic PBMCs,
1µg/ml PHA (Sigma) and IL-2 (1000U/ml). Clones were then expanded and maintained in
medium containing IL-2.
Real time quantitative RT-PCR. CD25
-
CCR6
+ 
T cells and autologous mDCs were isolated as
described above and incubated together or separately for 24 hours. Cells were then re-sorted
to separate T cells from mDC populations. Total RNA was extracted with the TRIzol method
(Invitrogen Life Technologies) according to the manufacturer’s instructions. cDNA synthesis
was performed by RT-PCR by using random hexamers and an MMLV transcriptase kit
(Stratagene). IL-10 transcripts were quantified by real time quantitative PCR on an ABI
PRISM 7700 Sequence detector (Perkin-Elmer Applied Biosystems), with applied
biosystems predesigned Taqman Gene Expression Assays and reagents according to the
manufacturer’s instructions. For each sample, the mRNA abundance was normalized to the
amount of 18S rRNA and is expressed in arbitrary units.
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Results
CCR6 is induced upon naïve T cell priming with tolerogenic cytokines
Tolerogenic T cell priming is thought to result in the induction of regulatory T cells. We
searched for phenotypic markers that were induced upon T cell receptor (TCR) activation in
the presence of tolerogenic cytokines and observed that TGF-β induces expression of CCR6
on proliferating T cells. We therefore analysed CCR6 expression requirements of human
CD4
+ 
naïve (CD45RA
+
, CD25
-
) T cells following TCR stimulation in the absence or presence
of TGF-β alone or combined with other immunomodulatory cytokines (IL-4, IL-12, IL-10).
We also assessed Foxp3 expression in these cells to address if cells were directed to the
natural Treg lineage. As shown in Figure 1 CCR6 was poorly induced in naive T cells
following activation with anti-CD3 and anti-CD28 antibodies or allogeneic DCs (not shown).
In contrast, CCR6 expression was specifically induced upon addition of exogenous TGF-β.
As previously described, TGF-β also induced Foxp3 expression, but importantly some
CCR6
+
cells remained Foxp3
-
, suggesting that at least a fraction of CCR6
+ 
cells is not directed
to the natural Treg lineage. Importantly, both CCR6 and Foxp3 expression induced by TGF-β
were prevented by the addition of polarizing cytokines IL-4, IL-12 or IFN-γ (data not shown).
Conversely, addition of IL-10 did not affect CCR6 induction by TGF-β, but partially
inhibited Foxp3 up-regulation. Thus, CCR6 expression following naïve CD4
+
T cell priming
requires TGF- β and is inhibited by TH1/TH2 polarizing cytokines but not by IL-10, but is
not necessarily linked to a commitment to the natural Treg lineage.
CCR6 is expressed on subsets of memory T cells and CD25
+ 
Tregs
We then analyzed CCR6 and Foxp3 expression ex vivo on human peripheral blood CD4
+
naïve, memory (CD45RA
-
CD25
+
) and regulatory T cells (CD25
+
). As expected, naïve CD4
+
T
cells were largely negative for both CCR6 and Foxp3 expression (Figure 2a). Memory cells
were also largely Foxp3
-
, but a consistent fraction of these cells expressed CCR6. Finally,
CD25
+ 
cells were enriched for both Foxp3
+ 
and CCR6
+ 
cells. Both CCR6
+ 
and CCR6
-
memory
cells were heterogeneous and contained TCM, TEM, gut and skin-homing cells (Figure 2b).
Conversely, CD103, the αE integrin subunit, that is also induced by TGF-β and mediates
adhesion to epithelia, was expressed only by a fraction of CCR6
+ 
cells. In conclusion, a large
fraction of antigen-experienced cells expresses CCR6 but not Foxp3 indicating that they do
not belong to the natural Treg lineage. Interestingly, circulating myeloid DC also expressed
CCR6 when analyzed ex vivo, suggesting that they might encounter CCR6
+
T cells in vivo
when attracted by CCL20 (data not shown). Consistent with previous reports, CCR6 was
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slightly down-regulated, upon in vitro maturation of DCs with LPS (data not shown).
CCR6 is lost following memory T cell priming with polarizing cytokines
We next addressed the stability of CCR6 expression of purified CCR6
+ 
memory cells
following proliferation in the presence of IL-7 and IL-15, homeostatic cytokines that drive
antigen-independent turnover, or following priming in the presence of either tolerogenic or
polarizing cytokines (Figure 2c). CCR6 was maintained upon expansion with homeostatic
cytokines or following priming in the presence of TGF-β, but was down-regulated upon
antigenic activation in the presence of polarizing cytokines. Reciprocally, CCR6
-
memory
cells remained CCR6
-
following cytokine-driven expansion or priming in the presence of
polarizing cytokines, but acquired CCR6 following priming with TGF-β with a similar
efficiency as CD4
+
naïve T cells (data not shown). Altogether, these results suggest that
CCR6 expression on T cells may be an indication that their previous antigenic contact has
occurred in a tolerogenic cytokine environment.
CCR6
+ 
T cells produce IL-2 and IL-10
We then compared the cytokine producing capacity of CCR6
+ 
and CCR6
-
memory cells to
that of naturally occurring CD25
+ 
Tregs (Figure 3a). CCR6
+
, CCR6
-
and CD25
+
Tegs were
purified by cell sorting and were stimulated for 24 hours with plate-bound anti-CD3 and anti-
CD28 antibodies. Cell-culture supernatants were then analysed for the presence of cytokines
by ELISA. IL-2 and IFN-γ were produced at high levels by both CCR6
+ 
and CCR6
-
memory
cells, but not by Tregs. Conversely, high levels of IL-10 were produced by CCR6
+ 
cells,
while CCR6
-
cells were poor IL-10 producers and, in contrast to CCR6
+ 
cells, also secreted
IL-4. As reported previously, Tregs produced IL-10, although perhaps at lower levels
compared to CCR6+T cells. Thus CCR6
+
T cells secrete cytokines associated with both
memory (IL-2, IFN-γ) and regulatory cells (IL-10). Furthermore, it was possibile to isolate a
subset of CCR6
+
T cells, co-expressing CCR4, which were characterized by expression of IL-
10 but not of IFN-γ, thus constituting a population of cells distinct from TH1 cells (Figure
3b). In contrast, CCR6
+
CCR4
-
cells were characterized by expression of IL-10 and IFN- γ .
CCR6
+ 
memory T cells proliferate with autologous DCs upon IL-10 neutralization
In order to understand if the CCR6
+ 
memory population contained cells that were
autoreactive, we incubated purified CFSE-labelled T cell subsets with ex vivo isolated,
autologous myeloid DC as a physiologically relevant source of self-antigens. After 5 and 7
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days T cell proliferation was assessed by analyzing CFSE dilution by flow cytometry. CCR6
-
memory cells proliferated very poorly or not at all in the presence of autologous mDCs, but
they proliferated extensively upon allogeneic stimulation (Figure 4a). In contrast, CCR6
+ 
T
cells were able to proliferate in the presence of both types of mDCs, but proliferation with
autologous mDCs required addition of neutralizing anti-IL-10 antibody. Thus, IL-10
produced by either mDCs or T cells inhibited proliferation of autoreactive T cells contained
within the CCR6
+ 
population. Analyses of IL-10 mRNA indicated that IL-10 was induced in
T cells but not in myeloid DCs following T-DC co-culture, thus indicating that IL-10 was
derived from activated CCR6
+ 
T cells (Figure 4b). Interestingly, the presence of anti-IL-10
antibody was not required for proliferation of CCR6
+ 
T cells induced by allogenic DC (Figure
4a). This different requirement for IL-10 neutralization was associated with low IL-2 but not
with higher IL-10 production in autologous compared to allogeneic cultures (Figure 4c),
suggesting that IL-2 produced in autologous cultures is insufficient to bypass the inhibitory
effects of IL-10. Consistently, addition of exogenous IL-2 led to vigorous proliferation in
autologous DC-T cell cultures in the absence of anti-IL-10 antibody (Figure 4a). Although
requirements for IL-10 neutralization differed for T cell proliferation induced by allogeneic
or autologous DC, both types of proliferation were MHC class II-restricted, IL-2-dependent
and were under the control of natural Tregs (Figure 4a). We conclude that CCR6
+ 
T cells
produce IL-10 in response to self-antigens presented by autologous DCs and inhibit
autoreactive T cell proliferation in an IL-10 dependent manner.
Treg and CCR6
+ 
T cell proliferation differ in requirements for exogenous IL-2
Natural Tregs are believed to be biased towards autoreactivity, to lack secretion of IL-2 and
to be anergic. We compared proliferation requirements of CCR6
+ 
memory T cells and CD25
+
Tregs in response to autologous and allogeneic DCs (Figure 4a). Unlike CCR6
+ 
T cells,
proliferation of CD25
+ 
Tregs in response to both autologous and allogeneic mDCs required
addition of exogenous IL-2, consistent with previous work reporting their anergic state in
vitro. In order to rule out the possibility that CCR6
+
T cells proliferating with autologous
mDCs were due to Foxp3
+
CD25
-
Tregs (Figure 2), we analyzed Foxp3 expression of
proliferating CCR6
+ 
T cells and CD25
+ 
Tregs following expansion with autologous mDCs.
We observed that autoreactive and alloreactive proliferating CCR6
+ 
T cells were largely
Foxp3
-
(data not shown), while the fraction of Foxp3
+ 
Treg proliferating in vitro with
autologous or allogeneic DC was similar to the fraction expressing Foxp3 ex vivo (data not
shown). Altogether these results show that both CCR6
+ 
memory T cells and CD25
+ 
Tregs
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contain autoreactive cells but possess different requirements for proliferation for exogenous
IL-2.
Antigen-specificity of CCR6
+ 
and CCR6
-
memory T cells in health and disease
In order to confirm that CCR6
+ 
T cells can react to innocuous and self-antigens, we assessed
T cell proliferation induced by recombinant antigens presented by non-professional APCs.
We stimulated CFSE-labelled purified T cell subsets with purified autologous monocytes
that, unlike myeloid DCs, are poor inducers of autoreactive T cell proliferation, but are able
to present purified antigens at high concentrations to induce proliferation of antigen-specific
T cells (Figure 5a). Responses to recall antigens such as tetanus toxoid were generally
detected in both CCR6
+ 
and CCR6
-
T cell subsets. In contrast, responses to the melanocyte-
derived self-antigen MelanA were detected exclusively among CCR6
+
T cells in all normal
donors tested. Interestingly, in patients affected by the autoimmune disorder Vitiligo, both
CCR6and CCR6
+ 
T cells responded to MelanA (Fig. 5b). Thus, cells specific for innocuous
antigens are contained within the CCR6
+ 
population in healthy donors but may become
partially CCR6
-
in an autoimmune pathology.
Recall antigen-specific CCR6
+ 
T cells cross-react with self-antigens
We next investigated whether autoreactive and recall-specific T cells represented two distinct
populations within CCR6
+
T cell, or if recall antigen-specific CCR6
+ 
T cells could cross-react
with self-antigens. We therefore re-stimulated with tetanus toxoid cells that expanded upon
stimulation with autologous DC. Response to MelanA is also shown as a control (Figure 6a).
A small fraction of auto-reactive T cells secreted cytokines upon re-stimulation with tetanus
toxoid, but not with autologous monocytes alone, showing that some auto-reactive CCR6
+ 
T
cells are specific for recall antigens. Single cell cloning of these auto-reactive, TT-specific
cells was performed and clones were analyzed for proliferation and cytokine production
following stimulation with self-ligands or tetanus toxoid. Two representative clones are
shown in Figure 6b-d. These clones secreted mainly IL-10 following re-stimulation with
autologous mDCs, and in these conditions showed low proliferative capacity, evaluated as 
3
H
incorporation, only upon addition of an anti-IL-10 antibody. In contrast the same clone
displayed high proliferative capacity following stimulation with moncytes in the presence of
tetanus toxoid and secreted IL-2 in these conditions. We conclude that CCR6
+ 
memory T
cells contain cells specific for self-antigens that can cross-react with recall antigens. The
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behaviour of these cells differs greatly when in the presence of self versus recall antigens,
suggesting that they might possess distinct roles in these different contexts.
Discussion
Here we show that CCR6 expression is induced in TCR activated naïve CD4+T cells in the
presence of TGF- β alone or combined with IL-10. In contrast, addition of TH1 or TH2
polarizing cytokines completely abolished CCR6 induction by TGF-β . These in vitro
generated CCR6
+
T cells were heterogeneous for Foxp3 expression, indicating that CCR6
induction by TGF- β does not necessarily correlate with Foxp3 expression and thus with
generation of Tregs. Analyses of CCR6
+
T memory cells from human peripheral blood
showed that, upon ex vivo TCR stimulation, these cells produce high levels of IL-10 and
IFN-γ and are largely Foxp3
-
. Furthermore, it was possible to identify a sub-population of
CCR6
+ 
T cells, co-expressing CCR4, that secreted IL-10 but not IFN- γ CCR6
+
CCR4
+ 
cells
thus constitute a subset of IL-10 producing cells distinct from TH1 or TH2 cells. In fact, IL-
10 was first described as a TH2-associated cytokine which could limit TH1 development by
inhibiting the activation and cytokine production of TH1 cells. It was further shown shown
that TH1 cells themselves can produce some levels of IL-10 and some time later, IL-10
production was associated to regulatory T cells and to maintenance of self-tolerance.
However, the exact role of IL-10 in Treg function is still not completely understood.
Adaptive, IL-10 producing Tregs were shown to develop following TCR activation in the
presence of an immunosuppressive environment, with reports suggesting an involvement of
IL-10 and TGF-β. It is known that TGF-β is a potent regulatory cytokine which inhibits
differentiation of T cells to the TH1/ TH2 lineage
59
. In fact, mice with a T cell specific
blockage of TGF- β signalling develop an autoimmune inflammatory phenotype associated
with CD4
+
T cell differentiation to TH1 or TH2 cells
60
. Interestingly it was also proposed that
IL-10 treatment enhances TGF-βRII expression on activated T cells, thus augmenting
responsivity to TGF-β
61
. However, in our experiments we generally did not observe an
enhancement of TGF-β induced CCR6 expression upon addition of IL-10. As the generation
conditions of CCR6
+
T cells in vitro resemble those reported for the generation of Tr1 cells,
we investigated whether cells expressing CCR6 possessed a regulatory function and if they
represented cells biased towards autoreactivity. Interestingly, CCR6
+
T cells proliferated
vigorously with circulating autologous myeloid DCs upon neutralization of IL-10. This
suggested the presence of autoreactive T cells among the CCR6+T cell population which
were normally blocked in their proliferation by T cell-derived IL-10. This phenomenon was
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generally observed for both IL-10 producing CCR4
+
CCR6
+ 
and IL-10/IFN-γ producing
CCR4
-
CCR6
+ 
T cells, with some variability between different donors (data not shown). Of
note, as APCs we used circulating myeloid DCs sorted directly from human peripheral blood,
as we can envisage that these cells have sampled antigens in vivo, and thus they presumably
constitute a physiologically relevant source of self-antigens. Compared to naturally occurring
CD25
+
Tregs, which are considered to be biased towards autoreactivity, the autoreactive cells
contained within the CCR6
+
T cell population do not require addition of exogenous IL-2 for
proliferation to self-antigens. Instead, they require neutralization of IL-10, which in contrast
has no effect on CD25
+
Tregs. In these particular experiments we cannot exclude that the
autoreactive CCR6
+
T cells, which constitute only a fraction of the total CCR6
+
T cells, are
unable to produce IL-2 themselves and utilize IL-2 produced by cells in the remaining
fraction. Furthermore, we show that in healthy donors, cells specific for the melanocyte
differentiation antigen MelanA are contained invariably within the CCR6
+
T cell pool,
whereas in patients affected by vitiligo MelanA specific cells are also present among the
CCR6
-
population. T cell mediated pathologies have been associated with a breakdown in the
critical balance between TH1, TH2 cells and regulatory populations. We show that, in vitro,
CCR6 expression on CCR6
+
T memory cells from peripheral blood of healthy individuals is
maintained in the presence of a tolerogenic environment such as IL-10 and TGF-β, while it is
down-regulated in these cells upon stimulation in the presence of TH1 or TH2 polarizing
cytokines. Reciprocally, CCR6
-
T cells up-regulate CCR6 to some extent in the presence of
IL-10 and TGF- β, while they remain CCR6
-
when stimulated in TH1 or TH2 polarizing
conditions. These results are consistent with our previous observations regarding the
requirements for the generation of CCR6
+
T cells in vitro from stimulated naïve cells. On the
basis of our observations, we speculate that in vivo, in healthy individuals, self-specific
CCR6
+
T cells may behave as in vitro and be blocked in their proliferation to self by
production of IL-10. Conversely, in autoimmune patients, the inflammatory environment may
cause differentiation of the self-specific cells towards TH1 or TH2 cells. These self-specific
cells may produce pro-inflammatory cytokines and be involved in the autoimmune
pathology.
Furthermore, we show that in donors which have previously been vaccinated against tetanus,
cells specific for the recall-antigen tetanus toxoid were detected among both CCR6
+ 
and
CCR6
-
memory pools. This is consistent with our previous reports showing that vaccination
against tetanus induces a mixed TH1/TH2 response detectable in all memory subsets
62 
. Thus,
we investigated at a single cell level whether CCR6
+ 
autoreactive or recall antigen specific T
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cells represented distinct populations. Interestingly, we obtained clones that presented a dual
specificity. On one hand they behaved as classical memory cells upon encounter of tetanus
toxoid they proliferated and produced IL-2, in addition to IL-10. On the other hand, when
stimulated with autologous mDCs, they produced IL-10 but not detectable levels of IL-2 and
proliferated upon neutralization of IL-10, although at low levels. Surprisingly, the levels of
IL-10 produced by these cells in the presence of self or recall antigens was similar. It must be
considered that upon encounter of self-antigens IL-10 is also consumed by the T cell, as
demonstrated by its proliferative block. Furthermore, we speculate that upon stimulation with
tetanus toxoid production of IL-2 by these cells may overcome the effect of IL-10. Of note,
these clones do not represent classical autoreactive cells as they do not proliferate with
autologous monocytes or with mDCs in the absence of IL-10 neutralization. The lack of
proliferation with autologous monocytes could be due to the presentation of different self-
peptides by monocytes compared to mDCs. In fact, it was previously reported that distinct
types of APCs may possess different proteases, leading to a differential expression of self-
peptides bound to their MHC molecules (ref). Alternatively, lack of recognition could be due
to the poor antigen presenting capacity of monocytes compared to mDCs. We generally
observed that neutralization of IL-10 has no effect on the proliferation of CCR6
+
T cells with
autologous monocytes (unpublished observation). We propose a context dependent function
of these CCR6
+
T memory cells. Upon encounter of a self-antigen, they exhibit a Tr1-like
suppressive capacity, thus limiting autoimmune reactions. Presumably, T cells will possess a
low affinity for self-antigens and this could explain the production of IL-10 and the lack of
production of detectable amounts of IL-2 in these conditions. In contrast, when exposed to
their specific antigen these cells will behave as memory cells and confer protection. Thus, we
propose that CCR6 expression on memory T cells may indicate that their previous
antigenic encounter has occurred in a tolerogenic environment. We speculate that this
mechanism may represent a strategy evolved by the immune system, which allows the
utilization of slightly autoreactive T cells, thus broadening the TCR repertoire available for
pathogen recognition, while lowering the risk of autoimmune reactions. In fact, CCR6
+
T cell
memory production of IL-10 upon encounter of self-antigen may raise their threshold for an
autoimmune response.
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Figures
Figure 1. CCR6 expression upon CD4
+ 
naïve T cell priming requires a tolerogenic
cytokine environment.
CFSE labelled peripheral blood naïve CD4
+
T cells were stimulated with anti-CD3 and anti-
CD28 for 4 days in the presence or absence of the indicated cytokines. Cells were stained at
d5 and analysed for CCR6 and Foxp3 expression by flow cytometry. Results are
representative of three experiments.
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Figure 2. CCR6 is expressed on CD4
+ 
T memory cells and CD25+Tregs and is lost
upon T cell priming with polarizing cytokines.
(a). Peripheral blood CD4
+ 
T cell subsets were analysed for CCR6 and Foxp3 expression by
flow cytometry. (b). Peripheral blood CD4
+
T memory cells were stained with antibodies
specific for CCR6, CCR7, CLA, b7, a4 and aE (CD103), and analysed by flow cytometry.
Shown is the percentage of CCR6
+ 
or CCR6
-
cells present in each subset. One representative
donor out of three. (c). Purified CCR6
+
T memory cells were assessed for CCR6 expression
at day 7 after stimulation with autologous DCs and TSST in the presence of TGF-β (black
line), IL-12 (grey line), IL-4 (dotted line), or following expansion in IL-7 and IL-15. Shown
is one representative experiment out of three.
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Figure 3. Ex vivo cytokine producing capacities of CCR6
+ 
and CCR6
-
memory cells and
CD25+Tregs.
(a) Purified CCR6
+
T memory cells and CD25
+
Tregs were stimulated for 24h with plate-
bound anti-CD3 and anti-CD28 and culture supernatants were analysed for presence of the
indicated cytokines by ELISA. (b) CCR6
+
T cells were furthermore subdivided according to
CCR4 expression. Purified CCR6
+
CCR4
+ 
and CCR6
+
CCR4
-
cells were analysed for
secretion of the indicated cytokines as described above. Indicated is one representative
experiment of at least three.
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Figure 4. CCR6
+ 
cells proliferate with autologous circulating myeloid DCs upon
neutralization IL-10. (a) Purified CCR6
+
, CCR6
-
 and CD25
+
T cells were incubated with ex
vivo isolated autologous or allogeneic myeloid DCs in the presence or absence of the
indicated antibodies or upon addition of IL-2. On day 7, CFSE profiles of T cells were
analysed by flow cytometry. (b) CCR6
+
T cells and autologous mDCs were purified after
24h of co-culture or of culture alone. IL-10 mRNA levels relative to 18S rRNA were
quantified by quantative real-time RT-PCR. Results are expressed in arbitrary units (AU) of
mRNA/rRNA. Single experiments representative of at least three are indicated. (c) Culture
supernatants of CCR6+T cells co-cultured with autologous or allogeneic DCs and were
assessed by ELISA for presence of IL-2 and IL-10. All experiments are representative of
three.
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Figure 5. MelanA specific cells are contained in the CCR6
+ 
population in healthy
individuals, whereas they are present also among CCR6
-
cells in vitiligo patients. Sorted
CFSE labelled CCR6
+ 
and CCR6
-
T cells from healthy individuals (a) or vitilgo patients (b)
were cultured with autologous monocytes with or without recombinant human MelanA,
tetanus toxoid (a) or TSST (b). CFSE profiles of CD3
+ 
CD14
-
cells were analysed on day 7
by flow cytometry. Shown are representative experiments of 10 healthy donors and 4
vitiligo patients.
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Figure 6. Autoreactive CCR6
+ 
cells contain tetanus toxoid-specific cells. (a)
Autoreactive CCR6
+
T cells were incubated with autologous monocytes with or without
Melan A or tetanus toxoid for 24h, in the presence of Brefeldin A. Intracellular staining was
performed using an anti-IL-2 antibody. Forward scatter (FSC) and staining for IL-2 of
autoreactive cells is shown. (b) Proliferation evaluated as 
3
H incorporation of two
representative clones is shown. Clones were stimulated with either myeloid DCs with or
without anti-IL-10 antibody, or with autologous monocytes with or without TT. (c) Culture
supernatants were assessed for presence of IL-2 and IL-10 by ELISA
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III. Conclusions and perspectives
Human CD4+T memory cells are extremely heterogeneous and can be subdivided into 
different subsets endowed with distinct immunological functions. 
In the first two manuscripts we identify distinct subsets based on expression of 
chemokine receptors and the IL-7 receptor. Among the TCM cells we distinguished 
between cells expressing CXCR3 or CCR4 which represent cells that are pre-committed 
to give rise to TH1 (pre-TH1) or TH2 cells (pre-TH2), respectively. These cells are 
capable of generating either TH1 or TH2 cells spontaneously in steady state conditions 
while they retain a certain degree of flexibility and can re-polarize to the opposite subset 
in the presence of antigen and of the appropriate polarizing conditions. Cells lacking 
expression of these chemokine receptors are largely unpolarized. These results further 
support the model previously proposed by Lanzavecchia & Sallusto stating that central 
memory cells represent a “stem cell pool” of antigen-primed cells which can rapidly 
generate new waves of effector cells. Furthermore our results shed light on the 
mechanisms allowing TH1 or TH2 polarization to be maintained from primary to 
secondary responses (manuscript 1). The model mentioned above also suggests that the 
generation of memory T cells occurs under a precise range of signal strength. We further 
analysed the stimulatory conditions driving the generation of memory cells and the 
phenotypic markers induced under these conditions. We observed that cells expressing 
CCR7 and the IL-7R possessed characteristics typical of memory cells. Furthermore, 
cells with this phenotype could be generated at both intermediate and strong stimulatory 
conditions and differed in their memory potential (Manuscript 2). Interestingly, cells 
receiving a strong or intermediate level of stimulation possessed characteristics of 
respectively pre- TH1 or unpolarized TCM cells, described by us in manuscript 1.
In manuscript 3 we consider another important aspect of immunological memory such as 
the maintenance of self-tolerance of CD4+T memory cells. Among these cells we 
identified a population of cells expressing CCR6 which are enriched in autoreactive T 
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cells. CCR6+T cells produce IL-10 in the presence of autologous myeloid DCs thus 
inhibiting autoreactivity in an IL-10 dependent manner. In healthy donors cells specific 
for the self antigen MelanA were detected exclusively among the CCR6+ subset while in 
patients affected by vitiligo these cells are also present among the CCR6- subset. 
Furthermore, we observed that autoreactive CCR6+T cells could cross-react to recall 
antigens. We identified autoreactive CCR6+T cell clones which respond to tetanus 
toxoid. These clones secrete IL-2 and proliferate vigorously in the presence of tetanus 
toxoid while they secrete IL-10 and inhibit their own proliferation in the presence of self 
DCs. These results suggest a context dependent role of CCR6+T cells, in that they exhibit 
a Tr1-like suppressive capacity when exposed to autologous DCs, while in the presence 
of their specific antigen they behave as memory cells. 
We would like to further address the context dependent behaviour of these cells. The 
results obtained so far seem to point out a role for IL-2 versus IL-10 production. We plan 
to investigate the regulation and the mode of action of these two cytokines, especially 
that of IL-10 which is still largely unknown.
Production of IL-10 but not IL-2 could also be a hallmark of the classical Tr1 cells 
described in the mouse system. In fact there are still no known surface markers which 
identify human Tr1 cells. Discovery of these surface markers would allow the isolation of 
Tr1 cells from human peripheral blood. Expansion of these cells in vitro and re-infusion 
in patients may prove to be a useful tool in immunotherapy for suppressing undesired 
immune reactions.
Furthermore, we wish to address the role of circulating myeloid dendritic cells in 
tolerance. We observed that self-reactive CCR6+ T cells proliferated in response to 
autologous mDCs but not to autologous monocytes upon neutralization of IL-10. The 
reason for this is currently unknown but we hypothesis that this may be due either to the 
poor antigen presenting capacity of monocytes compared to mDCs or the two cell types 
may differ in expression of self-antigens. In the latter situation there could be a role for 
the transcription factor AIRE in driving expression of self-antigens. 
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